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1 ABSTRACT 
 
 
Colorectal cancer is one of the most frequent malign diseases worldwide, accounting 
for thousands of incidences every year. The investigation of the expression of 
transporters capable of influencing cancer treatment could be more than a small 
contribution to better therapy and lead to a better prognosis of colorectal cancer in 
the future. 
In this respect, transporters of the organic anion transporting polypeptides 
(OATP) are interesting, as they mediate the transport of a broad spectrum of anionic 
substances, also including anticancer drugs to cancer cells. 
 Until now, 11 human OATPs have been detected. Their distribution in normal 
tissue as well as in neoplastic tissue has been the subject of many recent studies. 
Nevertheless little knowledge about their expression in colorectal cancer has been 
gained so far. However, the OATP superfamily is assumed to play an important role 
in efficacy of chemotherapy. Therefore, the subject of the present thesis was to 
investigate the expression of human OATPs on the mRNA level in three different 
sample types of tumor, namely human colorectal cancer (human colorectal cancer 
samples, with the adjacent healthy tissue, and colon cancer cell lines), human lung 
cancer, and human ovary carcinoma. Investigations are done by real time PCR and 
data are analyzed using Microsoft Excel®. The expression rates are expressed as 
MNE (mean normalized expression value), and consistently refer to the calibrators’ 
mean MNE value.  
 In colorectal carcinoma samples six transporters show upregulation in 
cancerous tissue, i.e. 1B3, 2A1, 3A1, 4C1, 4A1 and 5A1. Most remarkably, 
OATP1B3 exceeds the second threshold in four samples, showing expression rates 
ranging from MNE 4.32 up to MNE 8.27. The most conspicuous expression level 
could be demonstrated for OATP4A1, reaching a MNE value of 9.85. Remarkably, in 
the adjacent normal tissue from the colon cancer patients, upregulation of these 
OATPs is not detectable.  
Real time PCR studies in lung and ovary carcinoma cell lines show that 
OATPs 3A1, 1A2, 4A1, 4C1, and 5A1 are up regulated, but the expression rates are 
rather homogenous. The most surprising result is demonstrated for OATP3A1 in 
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DMS 456 cells (i.e. human small cell lung carcinoma cells). It shows a 14.7 fold 
upregulation.  
Taken together, the data shows that OATPs are widely expressed in colon 
cancer and the OATP superfamily might be taken as a marker during anticancer 
therapy.  
 
 
 
Das Kolorektalkarzinom stellt eine der häufigsten malignen Krankheiten weltweit dar, 
und zeichnet für tausende Krankheitsfälle jährlich verantwortlich. Die Expression von 
Transportern, die fähig sind die Effektivität von Chemotherapien zu beeinflussen, zu 
untersuchen könnte daher in Zukunft ein logischer und erforderlicher Beitrag zur 
Optimierung der Behandlung und Verbesserung der Prognose sein.  
 In dieser Hinsicht sind Transporter der organische Anionen transportierende 
Proteine („Organic anion transporting polypeptides“, OATPs) interessant, da sie die 
den Transport eines breiten Spektrums an oranischen, anionischen Substanzen 
vermitteln. Selbsterklärend zählen zu diesen auch die in der Krebstherapie 
verwendeten Arzneistoffe.  
Bis zum jetzigen Zeitpunkt wurden 11 humane OATPs entdeckt. Ihre Expression, 
sowohl in gesundem, als auch in entartetem Gewebe, war und ist Gegenstand vieler 
rezenter Studien. Nichtsdestotrotz ist bisher nur wenig über ihr Auftreten in 
Tumorgeweben bekannt. Da den Transportern jedoch eine große Rolle im Rahmen 
der Wirksamkeit von Chemotherapien zugeschrieben wird, war es Ziel der 
vorliegenden Arbeit die Expression der einzelnen OATPs auf mRNA Level zu 
untersuchen.  
Als Material fanden drei verschiedene Tumortypen Verwendung: humanes 
Kolonkarzinom und dessen umliegendes gesundes Gewebe, humanes Lungen- und 
Ovarialkarzinom. Die Forschungsergebnisse werden unter Verwendung der Real 
Time PCR Technik erzielt, und die Daten mit Hilfe von Microsoft Excel® ausgewertet. 
Die Ergebnisse werden durchwegs als „MNE“ (mean normalized expression value) 
und in Abhängigkeit vom mittleren MNE-Wert zweier Kalibratoren angegeben. 
In den untersuchten Kolorektalkarzinomproben der Patienten kann Hochregulierung 
von sechs Transportern, 1B3, 2A1, 3A1, 4C1, 4A1 und 5A1 nachgewiesen werden. 
Der Transporter OATP1B3 zeigt mit MNE-Werten zwischen 4.32 und 8.27 in vier 
 3 
Proben signifikante Hochregulierung, wobei die bemerkenswertesten Ergebnisse von 
OATP4A1 (MNE 9.85) erzielt werden. Interessanter Weise ist im umliegenden 
gesunden Gewebe der Kolonkarzinompatienten keine Hochregulierung dieser 
OATPs feststellbar.  
Zusätzliche Real Time PCR Screenings von Lungenkarzinom- und 
Ovarialkarzinom-Zelllinien zeigen, dass auch die Transportergene 3A1, 1A2, 4A1, 
4C1 und 5A1 hoch reguliert werden. Ungeachtet dessen sind die Expressionsraten 
durchwegs eher homogen. Besonders sticht allerdings die Expression des OATP3A1 
in der Zelllinie DMS 456 (Zelllinie des humanen kleinzelligen Lungenkarziom) mit 
14.7-facher Hochregulierung hervor.  
 Zusammenfassend zeigen die erhaltenen Daten, dass die Transporter der 
OATP Superfamilie im Kolorektalkarzinom weit verbreitet vorkommen, und daher 
zukünftig als Marker im Zuge einer Krebstherapie verwendet werden könnten.   
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2 AIMS OF THE THESIS 
 
 
Colorectal cancer is one of the most frequent malign diseases worldwide, accounting 
for thousands of cases every year. As dietary factors seem to play a vicious role in 
the formation of cancerous colorectal tissue, the highest incidence can be observed 
in the civilized Western countries.  
Colorectal cancer can be of hereditary origin, or it can be caused by inflammations in 
the gastrointestinal tract. In most cases, however, it appears without predisposition.  
The treatment of colorectal carcinoma is primarily surgical, obtaining a rate of 
success of approximately 75 %. In cases where surgical intervention does not lead to 
satisfying results, either palliative resection can be applied, or the patient needs to 
undergo chemotherapy. Most frequently, the fluoropyrimidines 5-fluoruracil (5-FU) 
and floxuridine, and thiotepa are applied (Lui et al., 2005). 
The organic anion transporting polypeptides form a group of transporter proteins of 
which 11 different human subtypes are known until now. They account for the 
transport of organic anionic substances, for instance bile salts or thyroid hormones. 
However, the most important aspect of this transporter superfamily is the fact that 
they are closely associated with drug absorption and excretion. Hence, they are 
considered to play an important role referring to drug-drug or drug-food interactions, 
drug side effects and drug efficacy in general. As the transporters’ expression is up-
regulated in certain tumors they might be the reason for inefficient chemotherapy, 
leading to poor prognosis for the patients, and also increased side effects.  
The expression of the 11 known human SLCO (solute carrier organic anion 
transporter family) genes is the objective of the present thesis. By investigating the 
expression rates in four different types of samples, including samples from cancer 
patients as well as established cancer cell lines, additional knowledge about the 
upregulation of the OATP family in cancerous tissues should be achieved. 
The aim of the thesis will be to elucidate the expression pattern of OATPs on the 
mRNA level by real time PCR. The results obtained by real time PCR then are 
analyzed by calculation programs. In addition attention will be paid on the distribution 
of the OATPs within the different sections of the colon to show whether upregulation 
of the transporter might be coupled not only with tumor stage but as well with the 
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tumor’s localization within the gut. OATP transporters therefore may act as tumor 
markers in future anticancer treatment.  
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3 INTRODUCTION 
 
 
3.1 The Organic Anion Transporting Polypeptides OATPs 
 
3.1.1 General Information 
 
The organic anion transporting polypeptides (OATPs in human, Oatps in rodents) are 
sodium-independent membrane transport proteins mediating the transport of various 
generally amphipathic organic compounds, including bile salts, organic dyes, thyroid 
hormones, steroid conjugates, anionic oligopeptides and numerous drugs, and other 
xenobiotics (Hagenbuch and Meier, 2003).  
In general, OATPs’ substrates are of high molecular weight (>450 KD) and 
show high plasma albumin binding under physiological conditions.  
Some OATPs are involved in the hepatic clearance of albumin-bound 
compounds (Meier and Stieger, 2002). However, most OATPs are expressed in a 
great number of tissues, including the blood-brain barrier, choroids plexus, heart, 
lung, kidney, placenta, testes and intestine. The liver specific OATPs/Oatps are 
localized at the sinusoidal (basolateral) plasma membrane domain of the 
hepatocytes. 
OATPs show 12 transmembrane domains (TM). All of them represent a large 
extracellular domain (extracellular loop 5, between TM 9 and 10) containing mostly 
conserved cystein residues with disulfide bonds,  N-glycosylation sites in extracellular 
loops 2 and 5, and the consensus superfamily signature between loop 3 and TM 6 
(Hagenbuch and Meier, 2003).  
In addition, Hagenbuch and Meier (2004) described that it consists of 643–722 
amino acids, and are glycosylated. Glycosylation has been demonstrated to influence 
membrane localization and transport function. Also intact disulfide bonds in 
extracellular loop 5 are important. Without these requirements the transporter is not 
expressed and shows no transport function (Hänggi et al., 2004). 
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OATPs/Oatps belong to the SLC21/SLCO gene family (solute carrier class) as 
members of the SLCO family (solute carrier organic anion transporter family) 
(Hagenbuch and Meier, 2004).  
 
The first Oatp has been identified and isolated from rat liver in 1994 by Jacquemin et 
al. Numerous additional OATPs/Oatps have been isolated from various species, 
including human, rat, mouse (Hagenbuch and Meier, 2004; Mikkaichi et al., 2004) 
cow (Geyer et al., 2006), horse (Brown et al., 2007), quail (Nakao et al., 2006), and 
other non-mammalian species (fruitflies, bees, nematodes, sea urchins, catfish, 
zebrafish, pufferfish, frogs, chicken, and pig).  
So far, Oatps were only found in species either belonging to the clade of 
protostomia or the clade of deuterostomia, but not in bacteria and yeast.  
Up to now, 11 human OATPs have been discovered and, following the new 
nomenclature systems (Hagenbuch and Meier, 2004), have been classified into 6 
families, OATP1 – OATP6. All together, 36 OATPs/Oatps have been identified in 
humans and rodents. 
 
 
3.1.2 Classification and Nomenclature 
 
Formerly, OATPs/Oapts have been named organ-specifically rather than functionally, 
creating similar terms for different gene products in different species on the one 
hand, and vice versa. By establishing a new species-independent system based on 
divergent evolution and defining an OATP/Oatp-gene superfamily that can be further 
Figure 1: A three-dimensional model of hOAT1 based on the structure of GlpT. (Perry et al., 
2006) 
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divided into sub-families and individual genes and gene products, further confusions 
can be avoided. This evolutionary based system of nomenclature has been approved 
by the HUGO Gene Nomenclature Committee (HGNC). 
Instead of using “SLC21/Slc21”, which does not permit classification in sub-
families, the root “SCL” is kept and extended with “O”, symbolizing the first letter of 
the abbreviation OATP/Oatp. Thus, the “SLCO/Slco” is used to classify genes, 
whereas “OATP/Oatp” stands for the corresponding protein. 
Genes, respectively proteins with >40% amino acid sequence identity are 
grouped in families and designated by Arabic numbering (e.g. SLCO1). Individual 
families include genes/proteins showing >60% amino acid sequence identity, and are 
designated by letters (e.g.SLCO1A). If the subfamily embraces further individual 
genes/gene products, additional Arabic numbering is added, based on the 
chronology of identification (e.g. SLCO1A1, SLCO1A2). 
Until the new nomenclature is broadly accepted and, most important of all, 
used, the familiar old names should supplement the new classification by being given 
in parentheses. (Hagenbuch and Meier, 2004) 
 
 
 
 
 
 
 
Figure 2: Phyllogenetiv classification and new nomencalture of human and rodent 
members of the OATP/SLCO superfamily (Hagenbuch and Meier, 2004). 
 9 
3.1.3 Function, physiological importance and pharmacological aspects 
 
As their name already indicates, OATPs/Oatps mediate sodium-independent 
transport (Jacquemin et al., 1994; Kullack-Ublick et al., 1995; Noé et al., 1997; 
Walters et al., 2000) of organic anionic compounds, but the mechanism of transport 
is not fully understood yet. It seems to be anionic exchange, coupling the uptake of 
organic compounds with the efflux of another (e.g. bicarbonate, glutathione and/or 
glutathione-S-conjugates) (Shi et al., 1995; Satlin et al., 1997; Li et al., 2000; Li et al. 
1998). 
All members of the OATP/Oatp superfamily seem to be able to mediate 
bidirectional transport while the direction of the substrates’ transport likely depends 
on the substrates’ local concentration gradients. In addition, the transport appears to 
be pH-dependent and electroneutral (Nakao et al., 2006). 
 
Most OATPs/Oatps mediate the transport of a wide range of amphipathic 
compounds. This broad and partially overlapping substrate specificity has been 
documented for mostly all members of the OATP1A- and OATP1B-subfamilies.  
Therefore, they might play an important role in overall drug absorption and 
disposition, together with the P-glycoproteins (MDRs/Mdrs) and the muldtidrug 
resistance associated proteins (MRPs, Mrps). 
Data provided by Fattinger et al. and Vavricka et al. (2000) indicate that co-
administration of specific OATP inhibitors may increase bioavailability of drugs 
otherwise being highly metabolized by hepatic first-pass effect.  
As a conclusion, OATPs/Oatps may have important effects on drug development and 
therapy. 
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  Substrates of the OATP superfamily 
     
OATP substrates   notes 
1A2 
APD-ajmalinium, atrasentan, bamet-R2, bamet-UD2, 
bilirubin, BQ-123, bromosulfophtalein (BSP), 
chlorambuciltaurocholate, cholate (CA), ciprofloxacin, 
CRC220, dehydroepiandroserone-3-sulfate (DHEAS), 
deltorphin II, [D-penicillamine-2,5]enkephalin (DPDPE), 
enoxacin, oestradiol-17β-glucuronide, oestrone-3-
sulfate, fexofenadine, gatifloxacin, gd-B20790, 
glycocholate (GCA), Levofloxacin, lomecloxacin, 
methotrexate, microcytin, N-methylquinidine, N-
methylquinine, norfloxacin, ouabain, pitavastatin, 
prostaglandin E2 (PGE2), reverse triiodothyronine (rT3), 
rocuronium, rosuvastatin, saquinavir, taurocholate 
(TCA), taurochenodeoxycholate (TCDCA), 
tauroursodeoxycholate (TUDCA), thyroxine (T4), TR-
14035, triiodothyronine (T3), unoprostone metabolite 
BQ-123, cyclic pentapeptide endothelin 
receptor antagonist;  
CRC220, peptidomimetic thrombin inhibitor; 
Gd-B20790, gadolonium-18-((3-(2-
carboxylbutyl)-2,4,6-triiodophenyl)amino)-
3,6,9-tris (carboxymethyl)-11,18-dioxo-3,6-
9,12-tetraazaoctadecanoic acid; 
TR-14035, α4β1/α4β7 integrin dual 
antagonist. 
1B1 
ACU154, arsenic (arsenite, arsenate), atrovastatin, 
atrasentan, bamet-R2, bamet-UD2, benzylpenicillin, 
bisgluvuronosyl bilirubin, bosentan, BQ-123, 
bromosulfophthalein (BSP), caspofungin, CDCA-NBD, 
cholate (CA), [D-Ala2, D-Leu5]enkephalin (DADLE), 
dehydroepiandroserone-3-sulfate (DHEAS), 
demethylphalloin, [D-penicillamine-2,5]enkephalin 
(DPDPE), enalapril, oestradiol-17β-glucuronide, 
oestrone-3-sulfate, fluvastatin, glycocholate (GCA), 
glycoursodeoxycholate (GUDCA), leukotriene C4 
(LTC4), leukotriene E4 (LTE4), methotrexate, 
microcystein, monoglyucuronosyl bilirubin, olmesartan, 
phalloidin, pitavastatin, pravastatin, prostaglandin E2 
(PGE2), rifampicin, Ro 48-5033 (bosentan metabolite), 
rosuvastatin, SN-38, taurocholate (TCA), 
tauroursodeoxycholate (TUDCA), thromboxane B2 
(TXB2), thyroxine (T4), TR-14035, triiodothyronine (T3), 
troglitazone sulfate, valsartan 
ACU154, metabolite of PKI166, an epidermal 
growth factor receptor kinase inhibitor; 
BQ-123, cyclic pentapeptide endothelin 
receptor antagonist; 
CDCA-NBD, chenodeoxycholyl-(Nε-NBD)-
lysine; 
Ro 48-5033, bosentan metabolite;  
SN-38, 7-ethyl-10-hydroxycamptothecin; 
TR-14035, α4β1/α4β7 integrin dual 
antagonist 
Table 1: Substrates of the OATP Superfamily. (Hagenbuch and Gui, 2008; Hagenbuch and Meier, 
2004) 
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Substrates of the OATP superfamily (continued) 
     
OATP substrates notes 
1B3 
amanitin, atrasentan, bilirubin, bosentan, BQ-123, 
bromosulfophthalein (BSP), CDCA-NBD, cholate 
(CA), cholecystokinin octapeptide (CCK-8), 
dehydroepiandroserone-3-sulfate (DHEAS), 
deltorphin II, demethylphalloin, digoxin, docetaxel, 
[D-penicillamine-2,5]enkephalin (DPDPE), enalapril, 
oestradiol-17β-glucuronide, oestrone-3-sulfate, 
fexofenadine, fluvastatin, fluo-3, glutathione (GSH), 
glycocholate (GCA), glycoursodeoxycholate 
(GUDCA), leuktrien C4 (LTC4), methotrexate, 
microcystin, monoglyucuronosyl bilirubin, 
olmesartan, ouabain, paclitaxel, phalloidin, 
pitavastatin, rifampicin, Ro 48-5033 (bosentan 
metabolite), rosuvastatin, taurocholate (TCA), 
taurochenodeoxycholate (TCDCA), 
taurodeoxycholate (TDCA), tauroursodeoxycholate 
(TUDCA), telmisartan, thyroxine (T4), TR-14035, 
triiodothyronine (T3), valsartan 
BQ-123, cyclic pentapeptide endothelin receptor 
antagonist; 
CDCA-NBD, chenodeoxycholyl-(Nε-NBD)-lysine; 
Ro 48-5033, bosentan metabolite; 
Fluo-3, glycine, N-[2-[[[[2-
[bis(carboxymethyl)amino]-5-(2,7-dichloro-6-
hydroxy-3-oxo-3H-xanthen-9-
yl)phenoxy]methyl]methyl]oxy]-4-methylphenyl]-N-
(carboxymethyl)-pentammonium salt; 
Ro 48-5033, bosentan metabolite; 
TR-14035, α4β1/α4β7 integrin dual antagonist 
1C1 
bromosulfophthalein (BSP), oestradiol-17β-
glucuronide, oestrone-3-sulfate, reverse 
triiodothyronine (rT3), thyroxine (T4), 
triiodothyronine (T3) 
  
2A1 prostaglandins, thromboxane B2   
2B1 
atrovastatin, benzylpenicillin, bosentan, 
bromosulfophthalein (BSP), CP-671,305, 
dehydroepiandroserone-3-sulfate (DHEAS), 
oestrone-3-sulfate, fexofenadine, fluvastatin, 
glibenclamide, M17055, pravastatin, pitavastatin, 
pregnenolone sulfate, prostaglandine E2 (PGE2), 
rosuvastatin, taurocholate (TCA), unoprostone 
metabolite 
CP-671,305, (+)-2-[4-({[2-(benzo[1,3]dioxol-5-
yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-
fluorophenoxy]-propionic acid; 
M17055, 7-chloro-2,3-dihydro-1-(2-
methylbenzoyl)-4(1H)-quinolinone 4-oxime-O-
sulfonic acid 
3A1 
benzylpenicillin, BQ-123, deltorphin, oestrone-3-
sulfate, prostaglandin E1 (PGE1), prostaglandin E2 
(PGE2), prostaglandin F2α (PGF2α), thyroxine (T4), 
vasopressin --- 3A1_v1 
arachidonic acid, BQ-123, prostaglandin E1 (PGE1), 
prostaglandin E2 (PGE2), thgyroxine (T4), 
vasopressin --- 3A1_v2 
BQ-123, cyclic pentapeptide endothelin receptor 
antagonist 
4A1 
benzylpenicillin, oestradiol-17β-glucuronide, 
oestrone-3-sulfate, prostaglandin E2 (PGE2), 
reverse triiodothyronine (rT3), taurocholate (TCA), 
thyroxine (T4), triiodothyronine (T3), unoprostone 
metabolite 
BQ-123, cyclic pentapeptide endothelin receptor 
antagonist 
4C1 cAMP, digoxin, methotrexate, ouabain, sitagliptin, thyroxine (T4), triiodothyronine (T3)   
5A1 substrates unknown   
6A1 substrates unknown   
 
 
 
 
 
 
 
 
 
Table 1 ctd.: Substrates of the OATP Superfamily. (Hagenbuch and Gui, 2008; Hagenbuch and 
Meier, 2004) 
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3.1.4 OATP sub-families and their members – functional properties 
 
 
OATP1A2, formerly named OATP-A, contains several rat and mouse members 
(Hagenbuch and Meier, 2004), and also one bovine homologue (Geyer et al., 2006). 
It is expressed at highest levels in brain (Kullack-Ublick, 1995; Gao et al. 2000), 
followed by liver (present in cholangiocytes, but not in hepatocytes (Lee et al., 2005)), 
the brush border of the distal nephron (Lee et al., 2005) and the apical membrane of 
enterocytes (Glaeser et al., 2007). It mediates the transport of a wide range of endo- 
and exogenous mainly amphipathic compounds, including bile salts, hormones and 
their conjugates, cyclic and linear peptides, toxins, organic cations and numerous 
drugs. Briefly, these are common OATP/Oatp substrates.  
OATP1B1 (OATP-C) was cloned from human liver (Tamai et al., 2000; Hsiang 
et al., 1999; Abe et al. 1999; König et al., 2000a) with orthologues in rat and mouse 
(Hagenbuch and Meier, 2004). It is considered to be a liver specific transporter (Abe 
et al 1999; Hsiang et al., 1999; König et al., 2000b), expressed in the basolateral 
membrane of the hepatocytes (Shi et al., 1995; Satlin et al., 1997; Li et al., 2000; Li 
et al., 1998; König et al., 2000b), as usual for liver specific OATPs/Oatps. The 
transport functions have been characterized in Xenopus laevis oocytes (Satlin et al., 
1997; Kullack-Ublick et al., 2001) and in stably transfected HEK-293 cells (Shi et al., 
1995; Satlin et al., 1997; Li et al., 2000). Its substrates include the common 
OATP/Oatp substrates, but are extended by eicosanoids, drugs such as benzyl 
penicillin, methotrexate, pravastatin and rifampicin, as well as the natural toxins 
microcystin and phalloidin (Hagenbuch and Meier, 2003). In addition, several 
polymorphisms in the SLCO1B1 gene have been described (Tirona et al., 2001; 
Nozawa et al., 2002) identifying a number of alleles with dramatically reduced 
Vmax/Km values indicating significantly decreased transport function. The basolateral 
expression of OATP1B1 depends on the liver-enriched transcription factor HNF-1α 
(Jung et al., 2001) explaining the 50% decrease of transcriptional expression of the 
transporter due to primary sclerosing cholangitis (Oswald et al., 2001). 
OATP1B3 (OATP8, LST-2) was cloned from human liver (Abe et al. 2001, 
König et al. 2000a) and holds 80 % amino acid identity to OATP1B1. It has also been 
detected to be a liver specific OATP (Tamai et al., 2000; Hsiang et al., 1999) which is 
highly expressed around the central vein (Abe et al. 2001; König et al. 2000a). In 
 13 
neoplastic tissue, the transporter was found in different tumour cell lines (gastric, 
colon, pancreas, gallbladder, lung and brain (Tamai et al., 2000)). It transports the 
same substrates as OATP1B1, exclusive of the intestinal peptide cholecystokinin 8 
(CCK-8) (Isamair et al., 2001) deltorphin and the cardiac glycosides digoxin and 
oubain (Fattinger et al., 2000). The substrate range has been investigated, as for 
OATP1B1, in Xenopus laevis oocytes and in stably transfected HEK-293 cells. 
Whether the increased expression around the central vein of the liver is related to a 
specific physiological function has not been investigated yet. The transporter is 
hepatically expressed depending on the levels of HNF-1α (Lee et al., 2005) and the 
bile acid nuclear receptor FXR/BAR (Jung et al., 2002). 
OATP1C1 (OATP-F) has one human and one rodent member (Hagenbuch 
and Meier, 2004). This transporter is expressed at the highest levels in brain and 
testes (Pizzagalli et al., 2002). In the latter, it is found in Leydig cells and the blood-
brain barrier (Tamai et al., 2000). Despite the common great variety of substrates, the 
OATP1C1 transports only a narrow range of compounds, including thyroid hormones, 
sulfobromophathalein (BSP), oestradiol-17β-glucuronide, and oestrone-3-sulfate. Its 
physiological role seems to be the delivery of thyroid hormones to their target tissues 
(Hagenbuch et al., 2007). 
OATP2A1 (the prostaglandin transporter PGT) contains single orthologues in 
rat and mouse (Hagenbuch and Meier, 2004; Schuster 2002). It has been cloned 
from adult human kidney and is expressed in numerous other tissues (brain, colon, 
heart, liver, lung, ovary, pancreas, placenta, prostate, skeletal muscle, spleen, small 
intestine). It mediates the transport of none of the typical OATP-substrates, but 
prostaglandins. The transporters’ physiological role is supposed to be the transport of 
prostaglandins and other eicosanoids. In addition, it possibly is involved in regulation 
of pericellular prostaglandin levels (Abe et al., 1999). 
OATP2B1 (OATP-B) shows orthologues in rat and mouse (Hagenbuch and 
Meier, 2004), and is ubiquitously expressed. It is found in human kidney (Abe et al., 
2001), lung, heart (Grube et al., 2006) liver (Pizzagalli et al., 2001), placenta (St-
Pierre et al., 2002) brain, spleen, testes, ovary, colon (Pizzagalli et al., 2001), and the 
ciliary body (Gao et al. 2005)).  
At physiological pH, it transports only a narrow range of substrates, including BSP, 
oestrone-3-sulfate, and dihydroepiandrosteron (DHEAS).  
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At acidic pH, however, also taurocholate, bilirubin conjugates, fexofenadine, statins, 
glibenclamide, and the loop diuretic M17055 are substrates (Hagenbuch and Gui, 
2008).  
OATP3A1 (OATP-D) contains orthologues in rat and mouse (Hagenbuch and 
Meier 2004), showing 97% amino acid sequence identity. Therefore, OATP3A1 is the 
most conserved protein within the OATP superfamily. Highest expression levels were 
reported from testes, brain, heart, lung, spleen, peripheral blood leukocytes, and 
thyroid gland (Adachi et al. 2003; Huber et al. 2007). It transports prostaglandins, 
thyroid hormones, the cyclic peptide BQ-123, and vasopressin. OATP3A1 might play 
an important role in transport of neuron-active peptides or thyroid hormones. 
However, additional studies are required to proof this hypothesis. 
OATP4A1 (OATP-E), with members in rat and mouse, is expressed in various 
tissues, reaching highest levels in heart, placenta, lung, liver, skeletal muscle, kidney, 
and pancreas. Additionally it has also been detected in brain. It mediates the 
transport of a narrow range of substrates including oestrone-3-sulfate, oestradiol-
17β-glucuronide, benzyl penicillin, PGE2, thyroid hormones (Fujiwara et al. 2001; 
Tamai et al. 2000), and might be important for the transport of thyroid hormones to 
the foetus, at least in the placenta. (Hagenbuch and Meier, 2004) 
OATP4C1 (OATP-H), contains orthologues in rat and mouse with 80% amino 
acid sequence identity in rat, and is kidney specific. It transports a narrow range of 
compounds, including digoxin, oubain, thyroxine, methotrexate, cAMP, and the 
dipeptidyl peptidase-4 inhibitor sitagliptin. As it also transports thyroid hormones, it 
might be important for their delivery to the kidney (Hagenbuch and Meier, 2004). 
OATP5A1 (OATP-J) represents the only member of the OATP5A subfamily. It 
consists of 848 amino acids. There is no further information available yet concerning 
its transport properties (Hagenbuch and Meier, 2004). 
OATP6A1 (OATP-I) shows highest expression levels in normal testes, and 
additional weak signals in spleen, brain, foetal brain, and placenta. It has been found 
in several lung tumours, lung cancer cell lines, and bladder and oesophageal 
tumours. Orthologues have been discovered in rat (Oatp6b1 and Oatp6c1). They 
transport taurocholate, dehydroepiandrosteron sulphate (DHEAS), T3 and T4. 
However, additional research is required to proof relatedness of the rat homologue to 
the human OATP6A1 (Hagenbuch and Meier, 2004). 
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Distribution of OATPs in cancer tissue/cancer cell lines 
  
     
OATP cancer tissue reference cancer cell line reference 
1A2 breast carcinoma Al Sarakbi et al. 2006 
T-47D, MCF-7, ZR-75-
1, MDA-MB-231, MDA-
MB-468 Miki et al. 2006 
  
  Miki et al. 2006 
MCF-10A, MCF-7, 
MDA-MB-231, ZR-75-1 Wlcek et al. 2008 
  
    MCF-7 Nozawa et al. 2005b 
  
endothelial cells of blood-
tumor barrier Bronger et al. 2005    
1B1 hepatocellular carcinoma Cui et al. 2003 MDA-MB-231, ZR-75-1 Wlcek et al. 2008 
1B3 
gastric, pancreatic, colon 
neoplasm Abe T et al. 2001 MDA-MB-231 Wlcek et al. 2008 
  gastrointestinal cancers 
Abe et al. 2001; Cui et 
al. 2003 
several cancer cell 
lines 
Abe et al. 2001; Cui et 
al. 2003 
  breast carcinoma Muto et al. 2007    
  lung cancer Monks et al. 2007    
2B1 
epithelia of invasive ductal 
carcinoma of mammary 
tissue Pizzagalli et al. 2003     
  
endothelial cells of blood-
brain barrier and blood-
tumor barrier Bronger et al. 2005     
  hepatocellular carcinoma Cui et al. 2003     
  breast carcinoma Al Sarakbi et al. 2006     
3A1 
  T-47D, MCF-7  Al Sarakbi et al. 2006 
  
  
MCF-10A, MCF-7, 
MDA-MB-231, ZR-75-1 Wlcek et al. 2008 
  
  T-47D  Nozawa et al. 2004c 
  
  MCF-7 
Nozawa et al. 2005b; 
Pizzagalli et al. 2003 
4A1 colon cancer Ancona et al. 2006 
MCF-10A, MCF-7, 
MDA-MB-231, ZR-75-1 Wlcek et al. 2008 
  
    T-47D Nozawa et al. 2004c 
  
    MCF-7  
Nozawa et al. 2005b; 
Pizzagalli et al. 2003 
4C1 breast cancer Wlcek et al. 2008 
MCF-7, MDA-MB-231, 
ZR-75-1 Wlcek et al. 2008 
5A1 breast cancer Wlcek et al. 2008 
MCF-10A, MCF-7, ZR-
75-1 Wlcek et al. 2008 
6A1 
lung tumor, lung cancer, 
bladder and oesophageal 
tumor Lee et al. 2004     
 
 
3.1.5 Aspects for OATPs in Drug Response 
 
OATPs mediate the transport of a great variety of mostly amphipathic organic 
compounds, including physiological substances as bile salts, hormones and their 
conjugates, but also xenobiotics (i.e. drugs).  
Table 2: Distribution of OATPs in Cancer Tissue and Cancer Cell Lines, respectively. 
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As uptake of drugs into cells is crucial for their therapeutic efficacy, altered function, 
OATPs may account for drug-drug interactions (inhibition/induction) or drug-food-
interaction. This needs to be closely investigated (Hagenbuch and Gui, 2008; Shitara 
et al. 2005; Smith et al. 2005b; Poirier et al. 2007). 
 
Altered function of the transporters may occur via genetic polymorphisms, embracing 
single nucleotide polymorphisms (SNPs) or haplotypes of the polypeptides. The 
resulting functional change in clearance organs as liver or kidney affects not only the 
drug’s concentration in blood and therefore its bioavailability, but also its toxicity. 
Decreased capacity of the transporters leads to increased plasma and tissue 
concentrations. The same effect can be observed due to increased uptake activity 
and/or decreased efflux (see figure 3). As an example, up to now more than 40 
mutations have been identified in SLCO1B1. On of these mutations results in 
decreased uptake of the HMG-CoA reductase inhibitor pravastatine into hepatocytes, 
leading to reduced inhibition of cholesterol synthesis and therefore degraded 
cholesterol-lowering effects. (Kazuya et al., 2008) 
 
 
 
 
 
 
 
 
Figure 3: The effect of a functional change in transporting activity on 
pharmacological and toxicological actions of drugs. (Kazuya et al., 2008). 
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3.1.6 Drug-drug interactions 
 
As OATPs/Oatps play an important role in the hepatic first pass clearance of 
numerous drugs, co-administration of specific OATP modulators may rise or lower 
oral bioavailability of highly metabolized compounds. 
Organic anion transporting polypeptides show broad substrate specificity with a 
certain degree of overlapping. By examining the Ki values of inhibitors of both OATPs 
and OAT (organic anion transporter) it could be demonstrated that cephalosporins, 
probenecid, cyclosporine A and rifampicin have the potential to lead to clinically 
significant drug-drug interactions (Shitara et al., 2005). 
Poirier et al. (2007) stated that inhibition of OATPs may result in altered 
pharmacokinetics, possibly interfering with drug safety and efficacy. However, the 
influence of the CYP enzyme family has to be considered as another factor of 
important influence on drug-drug interactions in the course of drug metabolism. 
Inhibition of some OATP/Oatp gene expression by rifampicin occurs via PXR-
receptors (i.e. pregnan X receptors). Therefore rifamycin may cause higher plasma 
levels, which on the one hand is desirable – concerning drugs being highly 
metabolized via OATP/Oatp mediated transport –, or on the other hand might lead to 
(more) adverse drug effects, decreased efficacy and/or therapeutic failure due to 
lowered uptake of the compound into its target tissue. Otherwise, induction may even 
increase the already strong first pass effect of OATPs/Oatps and lead to insufficient 
plasma levels. (Hagenbuch and Meier, 2004; Fattinger et al. 2000) 
 
 
3.1.7 Drug-food Interactions 
 
Dresser et al. (2002) reported for the first time that fruit juices are able to inhibit 
OATP1A2. Subsequently, studies have been performed on the effect of citrus juice 
and its components as well as of the influence of diverse flavonoids and herbal 
extracts on OATP1A2, OATP1B1, OATP1B3 and OATP2B1 (Hagenbuch and Gui, 
2008; Ismair et al. 2003; Satoh et al. 2005; Wang et al. 2005b; Fuchikami et al. 2006; 
Lu et al. 2006a; Bailey et al. 2007; Glaeser et al. 2007).  
Most flavonoids indeed inhibited the OATPs stated above. For instance, naringin 
inhibited the transport of fexofenadine via OATP2A1 (Bailey et al. 2007). Other 
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compounds, such as hesperidin from grapefruit juice (Bailey et al. 2007), biochanin 
A, genistein, and epigallocatechin-3-gallate (Wang et al. 2005), glycyrrhizin (Ismair et 
al. 2003), green tea and ginkgo extract (Fuchikami et al. 2006) showed an additional 
inhibitory potential on OATP1B1, OATP1B3 and OATP2B1 mediated transport.  
Hence, these results clearly suggest that transport via OATPs can be affected by the 
intake of fruit juices and this may lead to unexpected side effects and changes in 
bioavailability (Hagenbuch and Gui, 2008). 
 
 
3.1.8 OATPs and Cancer 
 
The organic anion transporting polypeptides family is broadly expressed in human 
tissue, in most members ubiquitously. They play a fundamental role in uptake of 
various substrates into cells, as well as their excretion and, therefore, in the course of 
body detoxification. 
Many studies have been performed yet to investigate the OATPs’ distribution not only 
in normal tissue, but also in cancer tissue and cancer cell lines. 
The majority of OATPs was found to be expressed in at least one malign tissue or 
cancer cell line. Their frequent expression of OATPs might play a key role in tumour 
genesis, possibly by rendering cells sensitive to hormonal growth stimuli. 
Further information about the individual OATP expressed in a certain tumor might 
bring useful information and improve the specific targeting of cytotoxic drugs 
(Hagenbuch and Gui, 2008).  
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4  METHODS AND MATERIALS 
 
 
4.1 Colorectal Tumor Tissue Samples 
 
Samples of stages of colorectal cancer are obtained from patients suffering from 
different stages of colorectal carcinoma, and are kindly provided by Prof. Dr. Enikö 
Kállay (Department of Pathophysiology, AKH Wien). Research investigation is 
approved by the hospital’s Ethics Committee.  
 
 
4.2 Cell Culture – Maintenance of Cells 
 
Materials 
 
 Roswell Park Memorail Institute (RPMI) 1640 Medium (PAN™ Biotech GmbH, 
Aidenbach, GER) 
 Fetal bovine serum (FBS) (PAN™ Biotech GmbH) 
 Penicillin (10.000 U/ml) – Streptomycin (10.000 U/ml) Solution (P/S) 
(Gibco/Invitrogen, Carlsbad, CA) 
 Trypsin/EDTA Solution (10x) (Gibco, Carlsbad, CA) 
 10x PBS (phosphate buffered saline) pH 7.4 
  Potassium chloride (Merck, Darmstadt, GER)  2g 
  Sodium chloride (Merck)     80g 
  Potassium dihydrogen phosphate (Merck)   2g 
  Disodium hydrogen phosphate (Merck)   14.4g 
  ddH2O       ad 1 l 
 Dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO) 
 Cell culture flasks 25 cm² and 75 cm² with vented cap (Iwaki scitech div., Asahi 
Technoglass, Ltd., Tokyo, JP) 
 Sterile pipettes 10 ml (Bibby Sterilin Ltd., Stone, Staffordshire, UK) 
 Sterile centrifuge tubes 15 ml and 50 ml (TPP Techno Plastic Products AG, 
Trasadingen, CH) 
 Sterile Pasteur pipettes (VWR International, Darmstadt, GER) 
 Cryovials /Bibby Sterilin Ltd., Stone, Staffordshire, UK) 
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 Incubator Cytoperm Heraeus (Kendro Laboratories GmbH, Vienna, AT) 
 Centrifuge Hettich Rotixa/RP (Hettich AG, Bäch, CH) 
 Laminar air flow (Heraeus, Hanau, GER) 
 Mikroscope Olympus CK2 
 Cell strainers, 40 µm (Falcon™, Becton Dickinson Biosciences, San Jose, CA) 
 Eppendorf pipettes (Eppendorf AG, Hamburg, GER) 
 
 
4.2.1 General 
 
All cells are from the C205 cell line, i.e. human colorectal adenocarcinoma cells 
derived from a 70 years old person. Cell culture work is performed exclusively in the 
cell culture room, where access is only allowed to people wearing a lab coat. Every 
action performed on the cells needs to be done in a sterile cabinet, the laminar air 
flow (Heraeus, Hanau, GER). 
The cells were cultivated in either 25 cm² or 75 cm² flasks. They were incubated at 
standardized conditions (37°C, 5 % CO 2, 95 % relative humidity; incubator: Heraeus 
cytoperm 2). To avoid contamination of the cells with microorganisms, sterile 
conditions are applied and hands are disinfected with ethanol (70 %) before work. 
 
 
4.2.2 Thawing of Cells 
 
For long term storage cells are put into liquid nitrogen (– 196°C). When needed, cells 
should be thawed at 37°C at approximately the same velocity as they have been 
frozen. The thawed cell suspension is centrifuged at 1000 rpm for 3 minutes at room 
temperature and the supernatant is discarded. The cell pellet is resolved in 4 ml 
medium (RPMI-1640, containing 10 % FBS and 1 % penicillin/streptomycin (P/S)) by 
pipetting the suspension up and down several times. It is then transferred into a 
sterile culture flask (either 25 cm² or 75 cm²) and incubated at 37°C. 
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4.2.3 Maintaining Cells in Culture – Washing and Feeding 
 
To culture cells, RPMI 1640 (PAN™ Biotech GmbH) supplemented with 10 % FBS 
(fetal bovine serum) and 1 % P/S is used. The medium is exchanged approximately 
every third day. For this purpose, the cells need to be washed with PBS first. Both, 
PBS and the RPMI medium, shall be brought to room temperature before being put 
onto the cells to avoid stress for the cells. Cells are washed routinely once with the 
same amount of PBS as medium used. PBS is aspirated and fresh medium was 
added to the cells. When adding either PBS or medium, it is important to avoid 
putting the reagents directly onto the cells to avoid detaching them from the flask. 
Cells shall not be kept outside the incubator for a long time. To guarantee sufficient 
CO2 exchange in the incubator, the flasks are either closed with gas permeable 
screwtops, or non-permeable screwtops are left partially open.  
When the cells reach confluence (80–90%), they have to be split in order to avoid 
overgrowing and decease of cell growth.  
 
 
4.2.4 Splitting of Cells 
 
Before splitting cells, confluence must be checked by light microscopy. Cells are 
washed twice with PBS to remove dead cells and cell parts. To detach the cells from 
the flask, 1 ml (25 cm²) trypsin is added and the flask is incubated at 37°C for 
approximately 3 minutes. Afterwards the flask is rocked gently several times and 
detaching of the cells is watched under light microscope.  
After adding new medium (4 ml for a 25 cm² flask, 12 ml for a 75 cm² flask), two 
drops of cell suspension are put into a flask of small size. For a flask of medium size 
approximately 6 drops have to be added. The flasks then are incubated at 37°C 
again. 
 
 
4.2.5 Freezing of Cells 
 
For long term deposit cells are frozen when confluence is up to 80%.  
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The medium is aspirated and the cells are washed with PBS twice, which is aspirated 
again. Trypsin is added (1 ml for a small flask), followed by 3 minutes of incubation at 
37°C. The flask is agitated and detaching of cells is checked under light microscope. 
Thereafter, 4 ml medium are added to the trypsinized cells (serum inactivates 
trypsin), the cells are re-suspended by pipetting them up and down several times, 
and then transferred into a 15 ml centrifugal tube. The suspension is centrifuged at 
200 x g for 5 minutes at 4°C. The supernatant is di scarded and the tube containing 
the pellet is placed on ice.  
To freeze cells, a special freezing medium was prepared (table 4).  
 
 
 
800 µl medium (RPMI-1640)
100 µl FBS
100 µl DMSO
Freezing Medium C205
 
 
The freezing medium needs to be pre-cooled to 4°C. Cells are suspended in the 
medium by pipetting them up and down several times. Then cells are quickly 
transferred into cryotubes (1ml/tube) and kept on ice. It is essential to work quickly, 
because DMSO (i.e. dimethyl sulofoxide, used as a cryoprotectant) in the freezing 
medium seriously harms the cells. The cryotubes are transferred on –80°C, and for 
longtime storage the next day into liquid nitrogen (–196°C). 
 
 
4.3 Mycoplasma Testing 
 
Materials 
 
Agarose Gel Electrophoresis 
 
 Agarose UltraPure™ (Invitrogen, Carlsbad, CA) 
 10x Tris-acetate EDTA (TAE) buffer pH 7.2 
  TRIS (Merck, Darmstadt, GER)    96.8g 
  Sodium acetate (Merck)     54.5g 
   
Table 3: Preparation of Freezing 
Medium for C205 cells 
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EDTA (Merck)       7.6g 
  ddH2O       ad 2 l 
 Ethidium bromide (5 mg/ml) (Sigma-Aldrich Chemie GmbH, Steinheim, GER) 
 Gene Ruler™ 100bp DANN Ladder (MBI Fermentas, Vilnius, LT) 
 6x Loading dye solution (MBI Fermentas) 
 Transluminator and camera Herolab E.A.S.Y. 429K (Herolab, Wiesloch, GER) 
 Gel electrophoresis unit HE 133 (Hoefer, San Francisco, USA) 
 Power supply Power Pac 3000 (Biorad Laboratories, Hercules, CA) 
 Microwave oven MIK 4600 (Elin, AT) 
 
 
Before cells are frozen for longtime storage they needed to be tested for mycoplasma 
contamination. 
Mycoplasmas do not have a cell wall (Ryan et al., 2004) and therefore remain 
unaffected by many commonly used antibiotics, e.g. penicillin and other beta-lactam 
antibiotics which target cell wall synthesis.  
Contamination occurs frequently in cell culture due to contaminated media or 
individuals that work with the cells. Mycoplasmas induce cell alterations, including 
chromosome aberrations and changes in metabolism and cell growth. Severe 
contamination can destroy a whole cell line or, if remaining undetected, adulterate 
research results.  
Mycoplasm are the smallest bacteria (i.e. < 1 µm), and therefore are difficult to detect 
by microscopy. Methods used to test cells for contamination are with mycoplasma 
PCR detecting their DNA. 
In this thesis, the mycoplasma testing is performed using the Myco Sensor® PCR 
Assay Kit. To save resources several cell lines in culture are tested for mycoplasma 
contamination. 
 
The supernatant taken from the cell culture is boiled at 95°C for 5 minutes in a 
heating block (Eppendorf Thermomixer comfort). The reaction is done accourding to 
the Myco Sensor® PCR Assay Kit. To save reagents samples of 50 µl, requiring only 
5 µl of StrataClean, are used. The reagent is added to the sample, vortexed and 
centrifuged. 30 µl of the supernatant are transferred into an Eppendorf tube and 
either stored for further use at –20°C, or directly  processed.  
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According to the instructions given in the manual of Myco Sensor® Assay Kit, the 
master mix was prepared as follows:  
 
 
 
PCR water fill to 50 µl fill to 25 µl
MgCl2 (2.0 nM) depends on conc. µl depends on conc.* µl
10x Taq buffer 5.0 µl 2.5 µl
dNTP mix 1.0 µl 0.5 µl
Mycoplasma primer mix 2.0 µl 1 µl
internal control template 4.0 µl 2 µl
Taq Polymerase DNA (5 U/µl) 0.5 µl 0.25 µl
sample (or positive control) 5.0 µl 2.5 µl
total volume of reaction 50.0 µl 25.0 µl
MM halved amountsMaster Mix for a single PCR reaction
 
 
The MgCl2 solution available in the laboratory featured a concentration of 1 nM/ µl. 
To accomplish, for the required concentration of 2 nM 2 µl of Master Mix are added*. 
 
According to the instruction manual, 0.5 µl of Taq DNA polymerase with a 
concentration of 5 U/µl are used for one reaction, resulting in 2.5 U/0.5 µl. As half the 
amount of reaction volume is used, and 0.63 µl of Taq polymerase is added for one 
PCR reaction (see table 5).  
 
 
 
PCR water 13.9 µl 111.2 µl
MgCl2 (2.0 nM) 2.0 µl 16.0 µl
10x Taq buffer 2.5 µl 20.0 µl
dNTP mix 0.5 µl 4.0 µl
Mycoplasma primer mix 1.0 µl 8.0 µl
internal control template 2.0 µl 16.0 µl
Taq Polymerase DNA (5 U/µl) 0.63 µl 5.04 µl
sample (or positive control) 2.5 µl / µl
total volume of reaction 25.0 µl 200.0 µl
MM for 8 reactionsMaster Mix for a single PCR reaction
 
 
The reagents are pipetted into reaction tubes (eightstrip tubes). Tubes are sealed 
thoroughly and placed into the PCR cycler (Biometra Personal Cycler).  
 
Table 4: Preparation of Master Mix for Mycoplasma PCR and halved amounts. 
Table 5: Preparation of Master Mix for Mycoplasma PCR II – single reaction and 
amounts for 8 reactions 
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According to the manual, parameters for PCR are set as shown in table 8. For 
detection of the PCR products, an agarose gel is used. 
  
 
 
 
 
 
 
 
 
The results of the mycoplasma testing are all negative. Hence, none of our cell lines 
is contaminated. 
 
4.4 Spheroid Inducing Cell Culture 
 
To induce the formation of spheroids, the C205 cells need to be transferred from 
normal RPMI 1640 medium to serum free medium containing special growth factors, 
but lacking antibiotics and FBS. For this purpose, the growth factors EGF (epidermal 
growth factor) and FGF-2 (fibroblast growth factor) are applied. The C205 culture 
then is called “SPH” (for spheroid).  
Growth factors are stored as lyophilisates, from which stock solutions are prepared. 
Stock solutions are stored at –20°C in the cell cul ture room.  
To prepare EGF working solution, the stock solution (c = 2 µg/µl) is diluted 1:200. To 
2 µl stock solution 398 µl sterile double distilled water are added. This results in 400 
µl working solution with a concentration of 10 ng/µl.  
FGF-2 stock solution (25 ng/µl) is diluted 1:2.5. To 20 µl stock solution 5 µl of sterile 
double distilled water are added. This results in 25 µl working solution featuring a 
concentration of 20 ng/µl.  
 
As C205 cells stop growth at all when being put on SPH medium, no splitting step is 
done the medium is aspirated before cells are washed twice with PBS. Then, serum 
free RPMI is added (13 ml/flask) and the growth factors (13 µl EGF and 13 µl FGF-2) 
are dissolved into it. The appropriate amount of growth factor working solution has to 
be refreshed every third day, but the medium can be kept. 
Table 6: PCR cycling parameters Table 7: Preparation of 
Agarose Gel 
temperature time
94°C 30 sec
55°C 1 min
72°C 1 min
PCR Cycling Parameters (1 cycle)
agarose 0.450 g
buffer 360 ml
ethidium bromide 1.5 µl
Agarose Gel (~1.5 %)
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4.5 Protein Purification  
 
Materials 
 
 Protease inhibitor cocktail P8340 (Sigma, St. Louis, MO) 
 PBS (Merck, Darmstadt, GER) 
 1.5 ml reaction tubes (Biozym Biotech Trading GmbH, Vienna, AT) 
 Plastic vials Polyvials® (Zinsser Analytic GmbH, Frankfurt, GER) 
 Eppendorf centrifuge 5415D (Eppendorf AG, Hamburg, GER) 
 Lysis buffer (see below) 
 
 
To measure the expression of CD133, cells are cultured on serum free medium 
enriched with growth factors (EGF working solution, 10 ng/µl; FGF working solution, 
20 ng/µl) on day 1 and 3. Two 75 cm² flasks are cultured. 
Protein extraction is done on day 4 and 5. On day 4, total protein is extracted. On day 
5, both, cytosolic and membrane protein is extracted. 
All steps of protein purification are performed outside the cell culture room in the 
laboratory, however, working on ice. 
 
 
4.5.1 Protein Purification 1 – Total Protein 
 
Cells are washed twice with 10 ml of pre-cooled PBS (4°C). It is important to aspirate 
PBS quantitatively. For protein isolation, 1 ml of PBS is added and the cells are 
detached from the flask using a cell scraper. Thereafter, the suspension is 
transferred into a sterile 1.5 ml tube and centrifuged at 200 x g for 5 minutes at 4°C. 
The supernatant is discarded, and the pellet is resolved in 500–600 µl of lysis buffer 
(table 10). 
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PBS 5000 µl
Triton X-100 0.1%
protease inhibitor mix 0.1%
Lysis Buffer
 
 
 
To extract membrane proteins, the suspension is agitated on ice for 30 minutes and 
then centrifuged at 14.000 x g for 10 minutes at 4°C. The supernatant is transferred 
into a sterile 1.5 ml tube and kept frozen at –80°C . The pellet is dissolved in 500 µl of 
lysis buffer and stored at –80°C for possible furth er use, although.  
 
 
4.5.2 Protein Purification 2 – Cytosolic and Membrane Protein 
 
Cells are washed twice with pre-cooled PBS (4°C), a nd then lysis buffer (pH = 7.4) is 
added to the cells. 
First, stock solutions of Na2HPO4 and NaH2PO4 are prepared. 10 mM is the target 
concentration, wherefore both stock solutions are diluted to this concentration. The 
pH is adjusted to pH 7.4. All solutions are stored at +4°C. The lower pH at +4°C has 
to be adjusted again. Therefore 0.3 M saccharose is added to 50 ml of Na2HPO4/ 
NaH2PO4 buffer. Just before applying the lysis buffer to the cells, 2 µl/ml protease 
inhibitor mix is added.  
 
 
MW 177.99 g/l 1 M MW 342.4 g/l 1 M
ws 0.88995 g/500 ml 10 mM ws 5.1345 g/50 ml 0.3 M
MW molecular weight
MW 137.99 g/l 1 M ws weighted sample
ws 0.68995 g/500 ml 10 mM
Na2HPO4 (*2H2O) 
NaH2PO4 (* H2O)
Calculations for Lysis Buffer Preparation
saccharose
 
 
 
Table 8: Preparation of Lysis Buffer 
Table 9: Calculations for Lysis Buffer Preparation 
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Cells are detached from the flask using a cell scraper. The suspension is transferred 
into a sterile tube and put on ice. Homogenisation is done by repeated freezing and 
thawing, using liquid nitrogen and a heating block (Eppendorf Thermomixer comfort). 
The homogenate is centrifuged at 3.000 x g for 10 minutes at 4°C. The supernatant 
then is transferred into a Beckman Microfuge tube and centrifuged at 48.000 x g 
(equals 28.000 rpm for Beckman Optima TLX centrifuge) for 60 minutes at 4°C.  The 
supernatant, containing the cytosolic proteins, is transferred into a fresh tube again. 
The pellet containing the membrane proteins is resuspended in 50 µl of lysis buffer 
and stored at –80°C for further use.  
 
 
4.6 Bradford Protein Assay 
 
In the Bradford test the specific colorant Coomassie Brilliant Blue G bind to proteins 
via hydrophobic and electrostatic interactions.  
The detection limit of the Bradford Protein Assay is 1 µg protein/ml under optimized 
conditions (Spector, 1978; Read and Northcote, 1981). The sample should be free of 
detergents, e.g. SDS, triton or nonidet P-40. Detergents in a concentration higher 
than 0.1 % inhibit the specific binding of the staining reagent to the proteins, and 
therefore need to be removed before analyzing the sample.  
The staining reagent, Coomassie Brillant Blue G, appears mostly in protonated, 
cationic form in acidic solutions, and shows its absorption maximum at 470 nm (red). 
It balances with its anionic form. In contrast, by binding to the protein the anionic form 
of the staining reagents is stabilized, showing a new absorption maximum at 595 nm 
(blue) (Compton and Jones, 1985).  
As the extinction coefficient of the colorant-protein-complex exceeds the coefficient of 
the unbound colorant, the increase of absorption at 595 nm can be measured easily 
and with high sensitivity against the unbound staining reagent by photometry. 
Variations in the rate of yield concerning the formation of the colorant-protein-
complex are due to variability of the proteins. (Eckert and Kartenbeck, 1997) 
 
Samples and protein standard (i.e. IgG) are thawed on ice. For the standard curve,  
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5 µl, 10 µl, 15 µl and 20 µl of protein standard are pipetted into Eppendorff tubes and 
mixed with 1 ml of Bradford reagent, adding one tube containing only the reagent as 
starting point of the standard curve (blank). Every probe is analyzed twice.  
If the values fit into the standard curve, the volume of sample can be used for double 
specification. If the value exceeds the upper limit of the standard curve, fewer sample 
needs to be used, or the sample has to be diluted.  
Before measurement, the device settings need to be checked. The sipper has to be 
unlocked and the drip has to be opened. Sipping time is set to two seconds. At the 
end of the procedure, the sipper is washed once with distilled water, and once with 
pure Bradford reagent; afterwards the absorption is set to zero manually, and the 
measurement can be started.  
 
 
Table 10: Procedure for the Bradford Assay on Protein from Tissue Samples. 
sample ID spec. 1 spec. 2 note
calculation - average concentration of 
protein (µg/µl)
1 38,18 37,25  use 1 µl
2 23,37 24,97  use 2.5 µ l
3 18,40 19,60  use 2.5 µ l
4 27,71 28,27  use 2.0 µ l
1 31,48 20,74  dilute 1:2
2 19,11 22,76  use 1 µl
3 14,88 12,13  o.k.  [(14.88 + 12.13)/2]2.5 = 4.852 µg/µl
4 15,84 15,76  o.k.  [(15.84 + 15.76)/2]/2 = 7.88 µg/µl
1 21,29 23,07  dilute 1:10
2 8,51 9,86  o.k.  (8.51 + 9.86)/2 = 9.185 µg/µl
1 14,19 11,22  o.k.  [(14.19 + 11.22)/2]*10 = 141.9 µg/µl
a (1 µl) 14,8 16,91  o.k.  (14.80 + 16.91)/2 = 15.885 µg/µl
a (5 µl) 38,81  x
b (1 µl) 14,65 16,92  o.k.  (14.65 + 16.92)/2 = 15.785 µg/µl
b (5 µl) 36,39  x
sample ID sample
1 11.5.09 supernatant C205
2 11.5.09 dissolved pellet C205
3 12.5.09 cytosolic proteins C205
4 12.5.09 membrane proteins C205
5 669 T tissue samples
6 669 SH (colorectal carc.)
4th measurement, sample 1 and tissue samples
legend
Bradford Protein Assay - Results
1st measurement, using 5 µl of sample
2nd measurement, using altered volumes of sample
3rd measurement, using altered volumes of samples 1 and 2
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Due to complications referring to the storage of IgG antibody, no Western Blot has 
been performed. The results obtained by real time PCR will be confirmed by Western 
Blot in further investigations. However, these are not part of this diploma thesis.  
 
4.7 Polymerase chain reaction (PCR)  
 
Materials 
 
 RNase free water 
 Sense and antisense primer, 100 pmol/µl (MWG Biotech, Ebersberg, GER) 
 Taq Man gene expression assays (AB Applied Biosystems, Foster City, USA) 
 TaqMan® gene expression master mix (Applied Biosystems) 
 ABI PRISM™ optical 96-well plates and caps (Applied Biosystems) 
 ABI PRISM™ 7700 sequence detector (Applied Biosystems) 
 Safe seal tips (Biozym Biotech Trading GmbH, Vienna, AT) 
 Sigma laboratory centrifuge 4K15C (Linder Labortechnik, Vienna, AT) 
 
 
4.7.1 General Information 
 
Polymerase chain reaction (PCR) was invented by Kary Mullis in 1983 (Bartlett and 
Stirling, 2003), for which the Nobel Prize was awarded to Mullis. It is a technique 
central to molecular biology research currently used in a variety of applications 
ranging from cloning, gene expression analysis, genotyping, sequencing, 
resequencing, and mutagenesis. In addition, it is applied in diagnostics for infectious 
diseases and in forensic investigations. 
The instrument to perform real-time PCR and all chemistries used are products of 
Applied Biosystems Inc.  
Real-time PCR (RT PCR) gives the researcher the ability to monitor the progress of 
PCR as it occurs (i.e., in real time). Data is collected throughout the process, 
revolutionizing the PCR-based quantitation of DNA and RNA. Real-time PCR 
characterizes reactions by the point when amplification of a target is first detected 
rather than the amount of target accumulation throughout the progress. Hence, the 
higher the starting concentration of copy numbers of the cDNA, the sooner a 
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significant increase in fluorescence level can be observed. This is contrary to the so 
called “endpoint assay” or “plate read assay”, where the amount of accumulated PCR 
products at the end of all PCR cycles is measured. (Applied Biosystems Inc.) 
An outstanding advantage of real-time PCR is its sensitiveness. Whereas agarose 
gels’ resolution is rather poor, about 10 fold, real-time PCR can detect two-fold 
changes.  
Further advantages in comparison with traditional PCR technique are 
 
 collection of data in the exponential amplification phase, 
 direct proportionality of fluorescent signal to number of generated amplicons 
(i.e. cDNA copies), 
 cleaved probe providing a permanent record amplicication of an amplicon, 
 increase dynamic range of detection, and 
 no post-PCR processing necessary. 
(Applied Biosystems Inc.) 
 
 
4.7.2 Phases of PCR 
 
PCR can be broken up into 3 basic phases (figure 4): First, the exponential phase 
including the exact doubling of product and accumulation at each cycle (assuming a 
100% efficiency of reaction). The exponential phase is very specific and precise. 
Second is the linear phase, which shows quite high variability. From one cycle to the 
next components are consumed, thus the reaction is slowing down and the products 
begin to degrade. The last phase is the plateau, where the reaction ends and 
products begin to degrade. (Applied Biosystems Inc.) 
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During the exponential phase the product is doubled at every cycle. Throughout the 
process, components are consumed, namely at different rates for each replicate. The 
reaction slows down and the PCR product is no longer doubled at each cycle. This is 
when linear phase starts. Here the samples begin to diverge into their quantities. 
Each sample reaches the plateau at a different point due to different reaction 
kinetics.  
Whereas traditional PCR takes its measurements at the plateau phase, for real-time 
PCR it is a lot more precise to measure during the exponential phase (Applied 
Biosystems Inc.). 
 
  
4.7.3 Data Analysis 
 
To simplify the analysis of the data, the linear graph is changed to log scale, where 
the exponential phase of the reaction can be detected more easily. To analyze the 
samples, the baseline needs to be set either automatically or manually, as in my 
case. The baseline allows excluding the noise signals occurring at the beginning of 
amplification. If the baseline is set correctly, background signals can not distort the 
results.  The second step is to set the threshold, which can also be performed either 
automatically or manually. The threshold marks the number of cycles that are 
necessary to amplify the cDNA to the point where it is detectable by fluorescence. It 
is set in the middle of the linear domain of the log-scale, where the lines should be 
Figure 4: Phases of PCR amplification: exponential, linear, and plateau phase 
(Applied Biosystems Inc.) 
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parallel and each pair of lines (every sample is double-determined) should swap 
(Applied Biosystems Inc.). 
 
 
 
 
 
4.7.4 Calculation 
 
To calculate the results of the quantitation assays, either absolute or relative 
quantitation can be used (Applied Biosystems User Bulletin #2: Relative Quantitation 
of Gene Expression (PN 4303859)).  
Absolute quantitation is used to quantitate unknown samples by using a standard 
curve. In contrast, relative quantitation assays are used to analyze changes in gene 
expression in a given sample relative to another reference sample. Calculation can 
be performed by the standard curve method or by comparative CT method, which 
has been chosen in this case. By applying the CT method the need for a standard 
curve is eliminated. Hence, time and amount of work can be reduced.  
The difference between the standard curve method and the comparative CT method 
is the use of arithmetic formulas to achieve the results (Applied Biosystems Inc.). 
  
The amount of the target is normalized to an endogenous reference and set relative 
to a calibrator, and thus described as  
 
 
Figure 5a and 5b: Simplification of analysis by changing from linear to log scale. (modified 
after Applied Biosystems Inc.) 
(a) linear scale (b) log scale 
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The equation describing the exponential amplification of PCR is: 
 
 
Xn number of target molecules at cycle n 
Xo initial number of target molecules 
Ex efficiency of target amplification 
n number of cycles 
 
The threshold cycle is calculated as 
 
 
XT threshold number of target molecules 
CT,X threshold cycle for target amplification 
KX constant 
 
Calculation of the endogenous reference reaction by  
 
 
RT threshold number of reference molecules 
Ro initial number of reference molecules 
ER efficiency of reference amplification 
CT,R threshold cycle for reference amplification 
KR constant 
 
 
 
To correlate the threshold number of target molecules (i.e., XT) with the threshold 
number of reference molecules (i.e., RT), these values have to be divided:  
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Their exact values depend on various factors, namely 
 
 reporter dye used in the sample, 
 sequence context effects on the fluorescence properties in the sample, 
 efficiency of sample cleavage, 
 purity of the sample, and 
 setting of the fluorescence threshold. 
 
Hence, K does not need to equal one.  
To simplify the calculation, the efficiency of target and reference are assumed to be 
equal (EX = ER = E), leading to  
 
 
or 
 
 
XN Xo/Ro, the normalized amount of target 
(delta)CT CT,X – CT,R, the difference in threshold cycles for 
target and reference 
 
 
Via rearranging and division of XN for any sample q by XN for the calibrator (cb) the 
final equation is made out to  
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(delta delta) CT (delta) CT,q – (delta) CT,cb 
 
If the amplicon’s size is < 150 bp, the efficiency is close to one. Hence, the amount of 
target is given by the simple equation 2–deltadeltaCT (Applied Biosystems User Bulletin 
#2: Relative Quantitation of Gene Expression (PN 4303859)). 
 
 
4.7.5 Detection 
 
To detect the PCR products, two chemical approaches can be used. TaqMan® 
method (i.e. fluorogenic 5’ nuclease chemistry) enables the detection of by 
intercalating into the DNA double strands. Former intercalator deys detected both 
specific and nonspecific products. By improving TaqMan® chemistry fluorogenic-
labeled probes were introduced, using the 5’ nuclease activity of Taq DNA 
polymerase, detecting only specific amplicons and hence eliminating the need of 
post-PCR processing (Applied Biosystems Inc.). 
First, an oligonucleotide is constructed. It contains a reporter fluorescent dye on the 
5’ end and a quencher on its 3’ end. As long as the probe is intact, the proximity of 
quencher and reporter disables fluorescence by fluorescence resonance energy 
transfer (FRET) through space. When the probe encounters the target sequence it 
anneals to it downstream from on of the primer sites. As the primer is extended, the 
probe is cleaved by the 5’ nuclease activity of Taq DNA polymerase. The cleavage of 
the probe separates the reporter from the quencher, resulting in increasing 
fluorescence signals. In addition, the probe is removed from the target strand. Hence, 
the primer can continue to extend the template strand to its end. With every cycle 
more reporter dye molecules are cleaved from their respective probes, resulting in 
increasing fluorescence signals.  
The second method is SYBR Green I Dye Chemistry®. This dye immediately binds to 
all double-stranded DNA in the sample. The further the amplification progress 
advances and the more amplicons are produced, the more dye can bind. This results 
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in increasing fluorescence, direct proportional to the amount of amplicons. As the 
SYBR Green I Dye® binds to all double-stranded DNA in the sample it might give 
false signals due to impurities of the samples (Applied Biosystems Inc.). 
 
 
 
 
 
TaqMan® Chemistry is used for all eleven OATPs and for 3 out of 4 house keeping 
genes. The forth house keeping gene is analyzed using SYBR Green I Dye 
Chemistry® (Applied Biosystems Inc.). 
 
 
4.7.6 Implementation 
 
The cDNA, kindly allocated by the working group of Prof. Dr. Enikö Kállay features a 
concentration of 100 ng/µl. The target concentration for Real Time PCR is 5 ng/4 µl. 
Therefore, samples have to be diluted in two steps, i.e. once 1:1 with PCR water, 
reaching a concentration of 50 ng/µl, and secondly 1:40, resulting in a concentration 
of 1.25 ng/µl, which equals 5 ng/4 µl.  
Figure 6: How TaqMan® and SYBR® Green I Dye Assay work. 
(Applied Biosystems Inc.) 
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The master mix has to be prepared separately for every plate, naturally. As the assay 
varies depending on the target of interest, 15 different master mixes have to be 
prepared. It is essential to pipet the master mix just before usage, and to keep all its 
components on ice while working.  
 
 
 
2x PCR Master Mix 5 µl 575 µl
20x Assay (Primer/Probe) 0.5 µl 57.5 µl
PCR water 0.5 µl 57.5 µl
Master Mix RT-PCR
1 reaction x 115
 
 
The master mix is pipetted into a 1.5 ml Eppendorf tube first, followed by the 
appropriate amount of PCR water. Finally, the assay is taken out of the freezer and 
thawed, vortexed and dispersed into the solution. The whole master mix is vortexed 
carefully and then distributed to eight-strip tubes (8 x 84 µl), due to application of an 
eight-channel pipet to accelerate work. With this eight-channel pipet, 6 µl of 
respective master mix are pipetted into each well. The plate then is sealed with foil. 
All plates are pipetted at once to minimize working effort and reduce the frequency of 
freezing and thawing, which can harm the cDNA. In total, 15 plates are prepared by 
pipetting 4 µl of sample in each well, and sealing the plate with foil. Afterwards the 
plates are stored at –20°C for further usage.  
 
For investigation of the expression rates, the accordant gene expression assays are 
added into the wells. The plate is sealed with foil again with especial attention paid to 
not touching the foil. Before the plate can be placed into the real time PCR device it 
has to be centrifuged at 2000 x g for 1’.  
 
 
Step one: Denaturation Step two: Annealing/Extension
50° 2 min 95° 10 min 95°C 15 sec 60° 1 min
HOLD HOLD
40 Cycles
 
 
 
Table 12: Real Time PCR – Thermal Cycler Settings 
Table 11: Composition of Master Mix for RT-PCR 
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The results are exported into a Microsoft Excel® data sheet and analyzed with the 
kind help of Mag. Martin Svoboda. The relative quantities are expressed as MNE, i.e. 
mean normalized expression values (Muller et al., 2002), and refer to the average 
value of the calibrators.  
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5 RESULTS AND DISCUSSION 
 
 
The main objective of the present thesis is to investigate the expression rates of the 
eleven human SLCO genes on the mRNA level in samples from tumors and tumor 
cell lines, including human colorectal cancer samples, derived from patients 
hospitalized at the AKH Wien, human colon cell lines, human lung cell lines and 
human ovary cell lines.  
Extraction of RNA and preparation of cDNA is done by Mag. Martin Svoboda and 
other colleagues of the Department of Pathophysiology on the AKH Wien. cDNA can 
directly be used to perform real time PCR. The results obtained are analyzed using 
Microsoft Excel®.  
  
Some information about the cell lines I worked with are given in chapter 5.1 (see 
table 13). 
 
 
5.1 Cell Lines – A Short Characterization 
 
Apart from the twenty patient colorectal cancer samples, five colon carcinoma cell 
lines, eight lung carcinoma cell lines, and six ovarian carcinoma cell lines are used in 
the present investigations. All of them are established cell lines for laboratory use. 
Table 13 gives a brief overview of the cells’ most worth knowing details. 
 
 
 
NCI-H69 
Human small cell lung carcinoma, derived from a 55 years old Caucasian (CLS – 
Cell Lines Service Inc.) 
HBE Human bronchial epithelial cells (CLS) 
DMS-114 Human small cell lung carcinoma (CLS) 
DMS-456 Human small cell lung carcinoma (CLS) 
Table 13: Short Characterization of Carcinoma Cell Lines, used in the present investigations. 
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GLC-16 Human small cell lung cancer cell line (Berendsen et al., 1988) 
HEY cell lines 
Human ovarian carcinoma cell lines, derived from human ovarian cancer xenograph 
(HX-62), with demonstrated different degrees of resistance against alkylating 
chemotherapy agents (Cellutions Biosystems Inc.) 
 HEY Alimta  Demonstrated resistance against pemetrexed 
 HEY Cis  Demonstrated resistance against cisplatin 
 HEY Doce  Demonstrated resistance against docetaxel 
 HEY Etop  Demonstrated resistance against etoposide 
 HEY Pax  Demonstrated resistance against paclitaxel 
 HEY WT  Wild type 
Caco 2/15 
Human colorectal adenocarcinoma, isolated from a primary colonic tumor, derived 
from a 72 years old male Caucasian (CLS) 
Coga 1A 
Human colon carcinoma cell line, derived from a pT3 stage moderately differentiated 
carcinoma (Brozek et al., 2008) 
C205 
Human colorectal adenocarcinoma (colon, metastatic), derived from a 70 years old 
male caucasian (CLS) 
HT 29 Human adenocarcinoma (colorectal), derived from a 44 years old Caucasian (CLS) 
L174T 
Human adenocarcinoma (colon, colorectal), derived from a 58 years old female 
Caucasian (CLS) 
 
 
 
5.2 Expression of OATPs in Human Colon Carcinoma Cell Lines 
 
The results obtained by real time PCR were analyzed using Microsoft Excel. As the 
calibrator is arbitrarily set to the value of 1 the expression rates have to be 
understood as relative multiples. The abbreviation “MNE” stands for “mean 
normalized expression value”. The calibrator consists of a mixture of all 9 cell lines’ 
cDNAs to make the cells comparable among each other. MNE values are calculated 
according to the expression of the respective gene in the calibrator. 
 
 
 
 
 
 
 
Table 13 ctd.: Short Characterization of Carcinoma Cell Lines, used in the present investigations. 
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(a) OATP1A2 
(c) OATP1B3 
(b) OATP1B1 
(d) OATP2A1 
(e) OATP2B1 
(g) OATP4A1 (h) OATP4C1 
(f) OATP3A1 
Figure 7 a–h: Expression of OATP1A2 (a) ,1B3 (b), 1B1 (c), 2A1 (d), 2B1 (e), 3A1 (f), 4A1 
(g), and 4C1 (h) on mRNA level in Colon Cancer Cell Lines, shown in MNE values. 
Results were obtained by Real Time PCR. 
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Figure 7a shows the relative mRNA expression rates of the OATP1A2. Even though 
this transporter has been shown to be expressed in healthy tissue of liver and brain, it 
reaches an approximately 2.25 fold higher expression in a colon carcinoma cell line 
(i.e. Caco 2/15) compared to the calibrator. Nevertheless its expression in other colon 
carcinoma cell lines is below the detection limit. 
 
Figure 7b displays mRNA expression of OATP1B1. This transporter is considered to 
be liver specific. Via PCR screening its expression in HT29 colon carcinoma cell line 
could be assessed on the RNA level. However, it is only 0.3 fold higher than is the 
calibrator.  
 
Figure 7c depicts OATP1B3. mRNA expression of this liver specific transporter 
appeared in the colon carcinoma cell lines Coga 1A (3.8 fold), HT29 (4.8 fold), L174T 
(3.4), and with the lowest amplification levels also in C205 cells. As the transporter 
protein shows significant elevations in 3 out of 5 investigated tumor cell lines, it might 
be investigated as a tumor marker for future diagnostical aspects.  
 
Figure 7d illustrates the expression of OATP2A1 mRNA. This transporter is the 
prostaglandine transporter. Its expression are low in the cell lines, namely at 0.8 in 
Caco 2/15 cells and at 0.225 in Coga 1A cells, and its expression levels are below 
the expression limit in other cancer cell lines.  
 
Figure 7e presents OATP2B1 mRNA expression. It is one out of three transporters 
investigated that shows expression in every cell line, even levels are low. The highest 
Figure 8: Expression of OATP5A1 on 
mRNA level in Colon Cancer Cell 
Lines, shown in MNE values. Results 
were obtained by Real Time PCR. 
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expression rate is reached in Caco 2/15 cells with an approximately 1.8 fold increase 
compared to the calibrator.  
Also in C205 cells, a 0.25 fold expression is observed. Measurable expression levels 
could also be proven for L174T and Coga 1A cells. The OATP2B1 transporter, which 
is normally expressed in various healthy tissues, is clearly down regulated in tumor 
cell lines.  
 
Figure 7f depicts second out of three transporters with shwon expression on the 
mRNA level in all five tested colon carcinoma cell lines, namely OATP3A1. It reaches 
highest expression rates in L174T cells (1.4 fold) and Coga 1A cells (1.1 fold), while 
in C205 and HT29 cells only a 0.1 fold expression is observed.  
 
Figure 7g displays the third transporter which is expressed in every one of our 
investigated colon carcinoma cell lines, namely OATP4A1. It actually reaches the 
highest expression rates compared with the other transporters, showing a remarkable 
9 fold increase in the expression rate in Coga 1A cells as compared to the calibrator. 
The results are interesting as OATP4A1 has not been proven to be expressed in 
healthy colon tissue. The significant upregulation in tumor cells seems to be 
especially worthy for future investigations for of colorectal cancer diagnosis.  
C205, HT29 and L174T cells show approximately the same expression rate (1.9 fold 
increase compared to the calibrator). However, Caco 2/15 cells express the 
transporter at low levels (0.3 fold).  
 
Figure 7h illustrates the expression of OATP4C1 mRNA in Caco 2/15 cells only. The 
transporter could not be shown to be expressed in any other of the five cell lines, and 
only reached low levels (1.1 fold expression).  
 
Figure 8 displays OATP5A1 mRNA expression. It is interesting to see that this 
transporter is up-regulated on RNA level in L174T cells (0.5 fold) and in Coga 1A 
cells (0.16 fold) because very little is known about this only member of the OATP 5 
family.  
The expression of all known 11 human OATPs, including OATP1C1 and 6A1, was 
investigated. However, these two transporters did not show any expression on mRNA 
level at all.  
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In summary, the investigations showed that Caco 2/15, Coga 1A, C205, HT29 and 
L174T cell lines express at least four transporters each. In C205 cells OATP1B3, 
2B1, 3A1 and 4A1 were found. Five transporters were found in Caco 2/15 cells, 
namely OATP1A2, 2A1, 2B1, 4A1 and 4C1. HT29 cells expressed OATP1B1, 1B3, 
2B1, 3A1 and 4A1, L174T OATP1B3, 2B1, 3A1, 4A1 and 5A1, and 6 out of 11 
transporters were found in Coga 1A cells, namely OATP1B3, 2A1, 2B1, 3A1, 4A1 
and 5A1. 
Especially the transporters being expressed in all of the investigated colon carcinoma 
cell lines, namely OATP4A1, 3A1, 2B1, could be interesting concerning new ways of 
diagnosing colorectal cancer in early stages and to improve the patients’ prognosis. 
The combination of knowledge of the transporters’ substrates and the fact that certain 
OATPs are expressed in tumor tissue might help to find better chemotherapy 
strategies and avoid therapy failure due to drug resistance.  
 
 
5.3 Expression of OATPs in Colorectal Cancer Samples 
 
The aim of the investigation of the OATPs’ expression in tumor samples gained from 
patients suffering from colorectal cancer in different parts of their colon and 
progressed into different stages is to show whether there are differences between 
normal tissue and tumor tissue. To make the samples comparable two samples are 
taken from every patient, i.e. healthy tissue and a biopsy of the patient’s tumor. It is 
not necessary to extract RNA and convert it into DNA via reverse transcription 
because I receive cDNA kindly prepared by Prof. Dr. Enikö Kállay’s research group.  
The method to measure the expression both in healthy and in tumor tissue from one 
patient each allows two ways of interpretation: on the one hand a general overview 
whether the transporter is up-regulated in tumor tissue at all, and on the other hand 
whether there is a relation between normal tissue expressing OATPs and tumor 
tissue where they are expressed.  
The calibrator consists of a mixture of all eight samples’ cDNAs to make their values 
comparable among each other. The MNE values are calculated relative to the 
calibrators’ mean MNE values.  
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Figure 9 a–d : Expression of OATP1A2 (a), 2A1 (b), 1B3 (c), and 2B1 (d) in 
Colorectal Cancer Samples, shown in MNE values. Results were obtained by Real 
Time PCR. 
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Figure 10 a–d: Expression of OATP3A1 (a), 4C1 (b), 4A1 (c) and 5A1 (d) in Colorectal 
Cancer Samples, shown in MNE values. Results are obtained by Real Time PCR. 
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Figure 9a displays the expression of human OATP1A2 in only one sample, i.e. a 
rectum tumor sample (stage T2), with an expression level of 0.7 fold compared to the 
calibrator. The healthy tissue from the same patient does not show any expression of 
the transporter. This suggests that the malignant transformation might have an 
impact on the expression of OATP transporters. 
 
Figure 9b shows the expression of OATP2A1. In contrary to OATP1A2, this 
transporter is expressed in every single sample, regardless of its condition. The 
average expression rate in the normal tissue samples reaches a 1.80 fold enrichment 
compared with the calibrator, but the highest rate is shown in normal tissue of a 
patient suffering from cancer in the descending colon (stage T2). The tumor sample 
taken from this particular patient does not show significant upregulation of OATP1A2. 
The average level in tumor tissue amounts to 0.83 fold of that of the calibrator. 
Highest levels are derived from rectum cancer (stage T3) with a 2.45 fold enrichment.  
Taken together, there is no relationship between the expression in normal and 
in tumor tissue. Some patients show high levels of OATP2A1 in their normal tissue 
but do not exhibit upregulation in their tumor tiusse, and vice versa. With a rate of 
1.80 for tumor and normal tissue, versus 0.83 MNE, OATP2A1 is more than two fold 
higher expressed in normal tissue than in cancerous one.     
 
Figure 9c illustrates the expression of the OATP1B3. It is remarkable that the 
OATP1B3 is the only transporter investigated which shows a significant difference in 
expression comparing normal tissue to the tumor samples. The transporter appears 
in every, but two, cancerous tissues, and reaches high levels in the tumor. The 
highest expression rates can be stated for one rectum carcinoma (stage T3) and one 
sigma carcinoma (stage T3) sample, where the MNE exceeds a value of 8.0. Lower 
but still significant levels are shown for three further samples (adenoma descending, 
stage T1, and colon ascending, stage T3), reaching MNE values of around 4.0. 
These are followed by four probes showing an expression rate of about 2.0 in 
average, found in stage T4 colon ascending, stage T1 colon descending, stage T2 
rectum, and stage T4 transversum ascending. In average the expression rate 
amounts to 2.0, compared to an average of 0.3 MNE for normal tissue. In average, 
the expression rates are about 6 fold higher in cancerous than in the adjacent tissue, 
which makes the OATP1B3 an interesting candidate for being a tumor marker.  
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Figure 9d depicts the expression of OATP2B1. In contrary to OATP1B3, there is no 
significant difference between normal and cancerous tissue. The average expression 
rate in normal tissue (1.57) exceeds the tumor tissue’s rate (0.96) not even twofold. 
In only a few samples the expression in the carcinoma tissue rises slightly above the 
normal tissue levels. As the transporter therefore is not significantly up-regulated in 
cancerous regions, OATP2B1 does not seem to become useful for the diagnosis of 
colorectal cancer.  
 
Figure 10a represents the expression of the OATP3A1 gene. In 15 out of 20 cases 
the transporter is up-regulated in tumor tissue, in a few samples even to high extend. 
The highest levels can be stated for two samples of colon ascending (both of them 
stage T3) with 4.2 and 3.8 MNE, and a sample of colon descending (stage T3) with 
an MNE of 4.8. In average, the tumor tissue shows an expression rate of 1.96 
compared to 1.17 in normal tissue.  
 
Figure 10b, showing the expression of OATP4C1, depicts the only case where the 
transporter is mostly expressed in normal tissue, with the highest value of 3.95 MNE. 
However, in 8 out of 20 samples the transporter can not be detected neither in 
normal nor in tumor tissue.  
 
In figure 10c high expression of the OATP4A1 is shown in almost every sample. The 
MNE values exceed that of normal tissue. Most remarkable the expression rate 
amounts to 9.85 in a sample from colon descending (stage T1). An average of 2.44 
MNE can be seen in the tumor, compared with 0.46 MNE for normal tissue samples. 
This difference in expression seems to make the OATP4A1 a suitable target for 
colorectal cancer screening.  
 
Figure 10d displays the expression of OATP5A1. This transporter shows its highest 
expression in a colon descending sample (stage T3), by reaching a value of 5.0 
MNE. In general, the transporter is slightly higher expressed in cancerous tissue than 
in normal samples. However, as there does not exist much knowledge about this 
specific transporter, further research is required to be able to valuate its relevance in 
tumor therapy.  
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The transporters OATP1C1, 1B1 and 6A1 do not show any expression in any of the 
samples examined.  
 
 
5.4 Expression of OATPs in Human Lung Cell Lines 
 
 
Expression of SLCO genes on mRNA level is also assessed in five lung cell lines. 
Four out of five cell lines are human small cell lung carcinoma cells, one is derived 
from human bronchial epithelial cells. The expression of OATPs in lung cancer cell 
lines might be interesting as the lung surface is constantly exposed to a number of 
exogenous substances.  
The calibrator consists of a mixture of all five cell lines’ cDNAs to make the cells 
comparable among each other. MNE values are calculated according to the 
expression of the respective gene in the calibrator.  
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Figure 11 a–d: Expression of OATP1A2 (a), 2A1 (b), 2B1 (c), and 3A1 (d) on mRNA level in 
Human Lung Cancer Cell Lines, shown in MNE values. Results are obtained by Real Time PCR. 
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Figure 11a shows the expression of OATP1A2. The mean MNE value of the 
calibrator is calculated as 0.62. The highest expression is found in NCI-H69 cells with 
a MNE value of 2.53. In average, the expression of OATP1A2 reaches a value of 
0.91 MNE. This means a slightly lower expression rate of the OATP in the cell lines, 
pointing out that there is no significant amount of OATP1A2 expressed in the lung 
cell lines on RNA level, except in NCI-H69 cells.  
 
Figure 11b depicts the expression of OATP2A1. Again, the calibrator’s mean value 
(1.18) doubles the average values of the cell lines, with their highest measured 
expression in NCI-H69 cells with a MNE value of 1.79. The average of the expression 
rates only reaches a value of 0.68. This suggests that there is no significant 
expression of OATP2A1 in lung cancer cell lines. 
 
Figure 11c indicates that this seems to be true for OATP2B1 expression in lung cell 
lines as well, where no significant expression of this transporter can be found.  
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Figure 12 a–d: Expression of OATP4A1 (a), 4C1 (b), 5A1 (c) and 6A1 (d) on mRNA level in 
Human Lung Cancer Cell Lines, shown in MNE values. Results are obtained by Real Time PCR. 
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Figure 11d, however, demonstrates high expression of OATP3A1, which reaches a 
MNE value of 13.42 in DMS 456 cells. As the mean value of the calibrator equals 
only 0.91 MNE the expression of the transporter shows a significant upregulation. 
This is also reflected in the average value of the five cell lines (4.14), showing a 4.5 
fold higher expression in the cell lines than in the calibrator. The GLC 16 cell line 
(3.76) and the NCI H69 cell line (2.80) show the second highest expression rates.  
Remarkably, the transporter is also expressed in healthy lung tissue.  
 
Figure 12a shows the expression of OATP4A1. The calibrator, reaching a mean MNE 
value of 1.98 is exceeded by the expression rate in HBE cells (5.80). The other cell 
lines show expression as well; however, it is lower than the calibrator’s value and 
therefore can not be counted as a significant expression on RNA level. 
 
Figure 12b depicts the results from OATP4C1. It is remarkable that the calibrator 
shows a very high MNE value of 3.60. Expression in the cell lines GLC 16 and NCI 
H69 reaches values between 2.84 and 3.18.  
 
Figure 12c shows that the highest expression rate of OATP5A1 is reached in GLC 16 
cells (5.39). The further four cell lines show either no expression or low expression 
levels of 0.05 MNE DMS 114 cells. 
Verifying the obtained results, also by performing real time PCR on the basis of RNA 
gained from patient samples, could help to better understand the function of 
OATP5A1. 
 
Figure 12d depicts the expression rates of OATP6A1. The average MNE value of the 
calibrator (i.e. 1.26) exceeds that of NCI H69 cells (MNE 0.74). No expression can be 
detected in the other four cell lines. 
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5.5 Expression of OATPs in Ovary Cell Lines 
 
 
Comparative studies on the expression of OATPs on mRNA level are also done on 
six human ovary cell lines. Five of these six cell lines are made resistant against 
diverse anticancer substances, e.g. paclitaxel. The remaining cell line belongs to the 
HEY wild type. The calibrator consist of a mixture of all six cell lines’ cDNAs and 
makes the results obtained comparable to each other. The MNE values are 
calculated according to the expression of the respective gene in the calibrator. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
OATP4A1
0,00
1,00
2 ,00
3 ,00
4 ,00
5 ,00
6 ,00
7 ,00
HE
Y 
Al
im
ta
HE
Y 
CI
S
HE
Y 
Do
ce
HE
Y 
Et
op
HE
Y 
Pa
x
HE
Y 
W
T
Ca
lib
ra
tor
Ca
l ib
ra
to
r
H2
O
M
N
E
OATP3A1
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
1,60
HE
Y A
lim
ta
HE
Y 
CIS
HE
Y D
oc
e
HE
Y E
top
HE
Y 
Pa
x
HE
Y 
WT
Ca
lib
rat
or
Ca
libr
ato
r
H2
O
M
NE
Figure 13 a–c: Expression of OATP2A1 (a), 3A1 (b), and 4A1 (c) in Human Ovary  
Cancer Cell Lines, shown in MNE values. Results obtained by Real Time PCR. 
OATP2A1
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
4,00
4,50
5,00
HE
Y 
Al
im
ta
HE
Y 
CI
S
HE
Y 
Do
ce
HE
Y 
Et
op
HE
Y 
Pa
x
HE
Y 
W
T
Ca
lib
ra
to
r
Ca
lib
ra
to
r
H2
O
M
N
E
a 
b 
c 
 54 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13a, showing the expression of OATP2A1, points out an upregulation of the 
transporter. The average MNE value of the calibrator of 1.18 is approximately twofold 
higher than the expression in the HEY Alimta cell line (MNE 0.66). However, this cell 
line is the only one to express this transporter, and a twofold upregulation does not 
seem to be a significant marker for this cancerous tissue.  
 
Figure 13b depicts the expression of OATP3A1. Given that the average MNE value 
of the calibrator lies at 0.91, the MNE value of the SLCO gene 3A1 of 0.11 is about 8 
times lower and can not be count as a significant expression at all. However, it is 
remarkable that once again the HEY Alimta cell line is the only one to express the 
gene, actually.  
 
Figure 13c describes the expression of OATP4A1. As already stated when 
investigating colon cancer cell lines, colorectal cancer patient samples, lung cancer 
cell lines, this transporter is broadly expressed in every cell line being subject of the 
analysis. The calibrator’s MNE value lies at 1.98, which is already exceeded almost 
1.5 fold by the average MNE value of all ovary cell lines, that is to say 2.98. The 
highest levels could be shown the HEY Doce cell line (5.84), closely followed by the 
HEY Cis cell line (4.42). The other cell lines only show expression rates below the 
value of 2.0. Hence, in these the transporter does not seem to be valuable for 
diagnostic purpose.  
 
Figure 14: Expression of OATP 6A1 in Human Ovary Cancer Cell 
Lines, shown in MNE values. Results obtained by Real Time PCR. 
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The last figure, figure 14, depicts the expression of the OATP6A1. Contrarily to 
OATP4A1, this transporter only showed expression in one single cell line, this is to 
say HEY WT, with a MNE value of 1.24. As the calibrator’s value is 1.62, there is no 
upregulation in the transporter’s expression rate.  
 
The other transporters (OATP1A2, 1B1, 1B3, 1C1, 2B1, 4C1, and 5A1), do not show 
any expression at the PCR conditions applied.   
 
 
5.6 Discussion and Conclusion 
 
The investigations on the expression of the SLCO genes superfamily included four 
different sample types: human colorectal cancer samples derived from patients, 
human colorectal cancer cell lines, human lung carcinoma cell lines, and human 
ovary carcinoma cell lines.  
 
In most of the samples, the expression rates, expressed in MNE (mean normalized 
expression value), remain below the value of 2.0, which is set arbitrarily to divide the 
expression rates in three groups and categorize the PCR results.  
Group one, with MNE values ranging from 0.0 to 2.0 (first threshold), means no or 
very low expression rates.  
Group two, with MNE values from 2.0 to 4.0 (second threshold), indicates moderate 
upregulation of the transporters’ expression rates. These MNE values are considered 
to show a relevance of the transporter as tumor marker. Only a few samples, most of 
them within the group of colorectal cancer patient samples, but non within the group 
of normal tissue patient samples, exceed this second threshold. 
Group three encompasses transporters with high MNE values (>4.0, third threshold), 
and reflects significant upregulation of mRNA expression in a sample (see table14). 
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Expression of OATPs on RNA Level - Summary 
sample sample ID SLCO 
 
 
1A2 1B1 1B3 1C1 2A1 2B1 3A1 4C1 4A1 5A1 6A1 
Caco 2/15 2,24 0,00 0,00 0,00 0,09 1,83 0,00 0,12 0,28 0,00 0,00 
Coga 1A 0,00 0,00 3,84 0,00 0,23 0,01 1,09 0,00 9,02 0,16 0,00 
C205 0,00 0,00 0,06 0,00 0,00 0,29 0,06 0,00 1,83 0,00 0,00 
HT29 0,00 0,33 4,71 0,00 0,00 0,00 0,07 0,00 1,79 0,00 0,00 c
o
lo
n
 
ca
rc
in
o
m
a 
ce
ll 
lin
es
 
L174T 0,00 0,00 3,25 0,00 0,00 0,06 1,40 0,00 1,82 0,50 0,00 
330T 0,00 0,00 4,35 0,00 0,65 1,43 0,48 0,00 2,21 0,00 0,00 
330T 0,00 0,00 3,89 0,00 0,53 1,42 0,42 0,00 2,52 0,68 0,00 
589T 0,00 0,00 4,32 0,00 0,73 0,62 1,16 0,86 1,61 0,70 0,00 
613T 0,00 0,00 0,05 0,00 0,34 0,91 1,68 0,00 0,28 2,68 0,00 
407T 0,00 0,00 0,21 0,00 1,61 1,35 4,09 0,00 1,55 1,88 0,00 
234T 0,00 0,00 1,91 0,00 0,68 0,44 0,25 0,00 3,41 0,69 0,00 
395T 0,00 0,00 0,90 0,00 0,93 1,25 3,79 0,00 2,53 2,25 0,00 
583T 0,00 0,00 0,16 0,00 0,41 1,35 2,14 0,00 4,20 0,49 0,00 
527T 0,00 0,00 2,02 0,00 0,45 0,65 1,63 0,00 9,85 0,50 0,00 
591T 0,00 0,00 0,33 0,00 0,86 0,40 4,90 0,00 1,84 4,99 0,00 
604T 0,00 0,00 8,08 0,00 0,66 0,65 2,01 0,00 1,48 1,73 0,00 
689T 0,00 0,00 0,65 0,00 0,73 0,75 1,69 0,00 2,09 1,94 0,00 
611T 0,00 0,00 0,00 0,00 0,95 0,92 1,26 0,41 1,97 1,81 0,00 
593T 0,68 0,00 0,47 0,00 0,67 0,76 3,05 2,22 1,02 2,12 0,00 
578T 0,00 0,00 1,96 0,00 0,64 0,87 2,16 0,26 3,30 0,61 0,00 
573T 0,00 0,00 0,08 0,00 0,26 0,34 1,07 0,00 0,38 0,36 0,00 
548T 0,00 0,00 0,00 0,00 2,45 1,22 2,00 0,92 0,48 0,47 0,00 
669T 0,00 0,00 8,27 0,00 0,85 1,30 2,92 0,28 2,60 1,66 0,00 
604T 0,00 0,00 0,29 0,00 1,00 0,85 1,37 0,00 2,92 1,14 0,00 
co
lo
n
 
ca
rc
in
o
m
a 
pa
tie
n
t s
am
pl
es
 
305T 0,00 0,00 2,26 0,00 1,26 1,62 1,14 0,75 2,63 0,70 0,00 
330N 0,00 0,00 0,00 0,00 2,13 2,61 1,36 2,10 0,49 0,81 0,00 
330N 0,00 0,00 0,00 0,00 2,91 3,20 0,91 0,00 0,69 0,00 0,00 
589N 0,00 0,00 0,00 0,00 2,14 1,06 1,02 1,36 0,27 1,24 0,00 
613N 0,00 0,00 0,00 0,00 1,33 1,11 1,01 3,95 0,36 0,81 0,00 
407N 0,00 0,00 0,61 0,00 0,65 1,27 1,74 0,00 0,34 1,25 0,00 
234N 0,00 0,00 0,00 0,00 2,07 1,75 1,42 0,00 0,56 0,77 0,00 
395N 0,00 0,00 0,00 0,00 2,70 2,90 1,36 0,00 0,62 1,34 0,00 
583N 0,00 0,00 0,00 0,00 2,04 2,05 1,06 0,00 0,56 2,21 0,00 
527N 0,00 0,00 0,00 0,00 2,88 1,32 1,53 0,00 0,53 1,15 0,00 
591N 0,00 0,00 0,00 0,00 1,69 1,25 0,75 0,00 0,32 0,73 0,00 
604N 0,00 0,00 0,00 0,00 1,02 1,49 0,99 1,29 0,16 0,91 0,00 
689N 0,00 0,00 0,00 0,00 2,58 1,92 1,85 0,00 0,77 1,76 0,00 
611N 0,00 0,00 0,00 0,00 0,95 1,60 1,44 0,93 0,32 0,96 0,00 
593N 0,00 0,00 0,00 0,00 1,53 1,01 0,65 0,00 0,46 0,91 0,00 
578N 0,00 0,00 0,00 0,00 1,53 0,75 1,20 3,42 0,34 1,09 0,00 
573N 0,00 0,00 0,00 0,00 1,30 1,18 0,67 1,10 0,52 0,00 0,00 
548N 0,00 0,00 0,00 0,00 1,20 0,94 1,60 0,73 0,93 0,84 0,00 
669N 0,00 0,00 0,00 0,00 1,32 0,99 0,72 1,72 0,25 0,67 0,00 
604N 0,00 0,00 0,00 0,00 1,30 1,47 1,29 2,42 0,40 0,00 0,00 
n
o
rm
al
 
tis
su
e 
pa
tie
n
t s
am
pl
es
 
305N 0,00 0,00 0,00 0,00 2,80 1,56 0,78 3,11 0,33 0,64 0,00 
DMS 114 0,00 0,00 0,00 0,00 0,00 0,00 0,15 0,16 0,72 0,05 0,00 
DMS 456 0,00 0,00 0,00 0,00 0,86 0,00 13,42 0,06 0,01 0,00 0,00 
GLC 16 0,00 0,00 0,00 0,00 0,34 0,00 3,76 2,84 1,33 5,39 0,00 
HBE 1,10 0,00 0,00 0,00 0,39 0,00 0,57 0,00 5,80 0,00 0,00 l
u
n
g 
ca
rc
in
o
m
a 
ce
ll 
lin
es
 
NCI-H69 2,53 0,00 0,00 0,00 1,79 0,00 2,80 3,18 0,49 2,47 0,74 
HEY Alimta 0,00 0,00 0,00 0,00 3,96 0,00 0,11 0,00 0,81 0,00 0,00 
HEY CIS 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 4,42 0,00 0,00 
HEY Doce 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 5,84 0,00 0,00 
HEY Etop 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,48 0,00 0,00 
HEY Pax 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 1,62 0,00 0,00 
o
v
ar
y 
ca
rc
in
o
m
a 
ce
ll 
lin
es
 
HEY WT 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,90 0,00 1,24 
Table 14: Expression of OATPs on RNA Level – Summary. 
Yellow indicates first threshold (MNE <2.0), light blue indicates the second threshold (MNE 
2.0–4.0), dark blue indicates the third threshold (>4.0). All thresholds have been set 
arbitrarily. 
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In colorectal carcinoma cell lines, only three transporters show upregulation, i.e. 1A2 
(Caco 2/15 cell line), 1B3 (Coga 1A, HT29 and L174T) and 4A1 (Coga 1A). The most 
remarkable upregulation is demonstrated for the Coga 1A cell line, with an observed 
MNE value of 9.02.  
 
As the main aim of the present thesis is to investigate the expression of the OATP 
superfamily in colorectal carcinoma samples, derived from patients suffering from 
different stages of the carcinoma, the findings presented in this diploma thesis could 
be of further value. The detection of significant upregulation could help to ameliorate 
diagnosis in early stage and hence the patients’ prognosis. In case significant 
upregulation of the transporter can be demonstrated, it might be used as a marker on 
the one hand, and help to avoid drug-drug interactions, and drug resistance, 
respectively.  
In total six transporters are up-regulated in cancerous tissue, i.e. OATP1B3, 2A1, 
3A1, 4C1, 4A1 and 5A1. Most remarkably, OATP1B3 has high expression rates in 
four samples, with MNEs ranging from 4.32 up to 8.27.  
The most conspicuous increase in the expression level can be demonstrated for 
OATP4A1, reaching a MNE value of 9.85. In addition, this transporter shows 
upregulation beyond the second threshold level of MNE 4.0 in thirteen out of twenty 
samples. These results suggest that screening patients’ biopsy samples for 
upregulation of the transporter could become important in the diagnosis of colorectal 
carcinoma, particularly as upregulation is missing in the adjacent normal tissue. 
Although the upregulation can be correlated neither with tumor stage, nor with the 
tumor’s localisation within the colon, this could be due to the low number of samples. 
 
For another transporter, namely OATP1B3 and OATP3A1, also no significant 
expression on the mRNA level is seen in parts of the tissue.  
In any case, the results from the screening in the limited number of samples need to 
be verified by screening of a larger collection of samples. In addition, the 
transporters’ expression will have to be demonstrated on protein level, too, to make 
the results valid for raising future perspectives. Nevertheless these initial 
investigations suggest that the OATP superfamily may be further examined as future 
tumor markers. 
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In comparative studies, real time PCR analysis of OATPs is also done in lung and 
ovary carcinoma cell lines. As these two types of cancer belong to the most frequent 
causes of death worldwide, new screening methods and ways to diagnose the 
malignancy in early stages will definitely help to ameliorate the patients’ prognosis, 
which currently is quite poor in both cases.  
Concerning lung carcinoma cell lines, OATP3A1 provided the most astonishing 
result. It showed an expression rate of MNE 13.42 in DMS 456 cells, what denotes a 
14.7 fold upregulation compared to the calibrator. Additionally, OATP4A1, 5A1, 4C1 
and 1A2 showed higher expression rates. However, to verify these first findings a 
screening of lung carcinoma samples Is needed in the future.  
In comparison with the lung carcinoma cell lines, the results for OATP expression in 
ovarian cancer cell lines appear moderate. Only two transporters are up-regulated, 
namely OATP2A1 and 4A1. While the expression rate of OATP2A1 exceeded the 
first threshold simply in the HEY Alimta cell line, OATP4A1 showed MNE values 
beyond the second threshold (MNE 4.42 in HEY CIS, MNE 5.84 in HEY Doce).  
 
Taken together, mRNA the expression rates for OATPs demonstrated by real time 
PCR do not show broad upregulation of the transporters in cancerous tissue of the 
colon. However, these results might build the basis of more selective diagnostic 
methods. Concerning colorectal cancer therapy could be ameliorated by using the 
OATP superfamily as a marker, helping to avoid surgical intervention due to late 
diagnosis on the one hand, and enhancing the efficacy of chemotherapy by avoiding 
inefficient drug application due to resistance on the other hand. 
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6 SUMMARY 
 
 
Although colorectal cancer is one of the most frequent malign diseases worldwide, 
with the highest incidence in civilized Western countries, the prognosis of advanced 
metastazing colon cancer is still poor. After surgical resection of the cancerous 
tissue, application of anticancer chemotherapy is hampered by the development of 
drug resistance. Often drug resistance is due to the over or under expression of 
membrane transport proteins for cytostatic agents in the tumor cells. It is well 
established that over expression of ABC-efflux transporters causes drug resistance 
by mediating the rapid efflux of drugs from the cells. However, very little is known 
whether uptake transporters from the SLCO family might compensate increased 
efflux by an efficient uptake. Therefore expression of SLCO transporters is 
investigated in colon cancer cell lines and comparative studies are done in lung and 
ovary carcinoma cell lines. 
From the 11 known human SLCO (solute carrier organic anion transporter 
family) genes only three transporters show upregulation in colorectal carcinoma cell 
lines i.e. 1A2 in the Caco 2/15, 1B3 in the Coga 1A, HT29 and L174T and 4A1 in the 
Coga 1A cell line. The most remarkable upregulation is demonstrated for the Coga 
1A cell line, with an approximately 10-fold upregulation of OATP4A1. Remarkably, 
this transporter shows upregulation in thirteen out of twenty samples derived from 
human colon tumors, while its expression in the adjacent normal tissue is near the 
detection limit. Although, due to the low number of samples (n = 20), upregulation in 
colon tumors was not associated with tumor stage or localisation within the colon, 
these findings warrant further studies on OATP4A1 expression in colon cancer. 
OATP4A1 is also high in the ovarian carcinoma cell line HEY made resistant to 
cisplatin and doxorubicin, respectively. This further suggests that this transporter 
might be associated with resistance to anticancer drugs in solid tumors as well. Also 
in the lung carcinoma cell line HBE OATP4A1 is increased, while three other lung 
carcinoma cell lines over express OATP3A1 up to 14-fold (DMS456). Remarkably, 
also the “kidney” specific” transporter OATP4C1 is over expressed in lung cancer cell 
lines indicating the normal organ border of OATP expression is overcome during 
tumorigenesis.  Another transporter, namely OATP5A1, for which organ localization 
and substrates are not established yet, is found to be over expressed in lung cancer 
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cell lines as well as in colon tumor specimens. On the other hand, OATP2A1, the 
high affinity transporter for prostaglandins, is greatly down-regulated in normal colon 
tissues as compared to colon tumors, but it is also upregulated in the HEY cell line 
resistant to Alimta. These transporters regulate the levels of prostaglandins, like 
PGE2, as inflammatory mediators in the interstitiel space. OATP2A1 down-regulation 
could contribute to tissue inflammation driving tumor progression. 
In addition to the main objective of the present thesis on the expression of OATP 
transport proteins another task was to establish the spheroid model for drug 
screening. Spheroids were grown from established tumor cell lines and CD133 
(prominin) was used to screen for potential cancer stem cells in these cell cultures. 
These speroid cultures resemble the physiological parameters better than tumor cells 
grown in a monolayer culture, and they could provide a future model for studies on 
tumor therapy. 
In conclusion, the results of this thesis show the expression patterns of OATP 
transporters in human colon tumors and tumor cell lines from solid tumors, and 
provide the base for further functional studies on the role of OATPs in the therapy of 
human cancers. They may be integrated in the efforts made to reduce drug-drug, 
drug-food interactions and minimize drug side effects due to interactions with the 
transporter family.  
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